

Australia

Patents Act 1990
Patent Request : Standard Patent

We, the Applicants/Nominated Persons specified below, request we be granted a patent for the invention disclosed in the accompanying standard complete specification.

[70,71] Applicants/Nominated Persons:

Mycogen Corporation of 5501 Oberlin Drive, San Diego, California 92121, United States of America; and Kubota Corporation of 1-3, Nihombashi-Muromachi, 3-chome, Chuo-ku, Tokyo 103, Japan

[54] Invention Title:

Novel microorganism and insecticide

[72] Inventors:

Michio Ohba, Hidenori Iwahana, Ryoichi Sato, Nobukazu Suzuki, Katsutoshi Ogiwara, Kazunobu Sakanaka, Hidetaka Hori, Shouji Asano, Tadaaki Kawasugi

[74] Address for Service in Australia:

Spruson&Ferguson, Patent Attorneys
Level 35, St Martins Tower
31 Market Street
Sydney New South Wales Australia (Code SF)


Details of Basic Application(s)

[31] Appln. No(s):	[33] Country:	[32] Application Date:
193810/91	Japan	2 August 1991
915203	United States of America	23 July 1992

DATED this Twenty-fifth Day of June 1996

Mycogen Corporation
Kubota Corporation

By:


Registered Patent Attorney

675628

SPRUSON & FERGUSON

Australia

Patents Act 1990

Notice Of Entitlement

I, John David O'Connor, of 31 Market Street, Sydney, New South Wales, 2000, Australia, Patent Attorney for the Applicant/Nominated Person in respect of Application No. 24116/92 state the following:-

The Applicants/Nominated Persons have entitlement from the actual inventors as follows:-

In respect of the invention disclosed in the basic application filed in Japan, Mycogen Corporation is the assignee of a part interest in the invention from Kubota Corporation which is the assignee of the actual inventors. In respect of the invention disclosed in the basic application filed in the United States of America, Mycogen Corporation and Kubota Corporation are the assignees of the actual inventors.

The Applicants/Nominated Persons are entitled to rely on the applications listed in the Patent Request as follows:


Kubota Corporation is the applicant of the basic application filed in Japan and is an assignee of the basic applicants in respect of the application filed in the United States of America. Mycogen Corporation is the assignee of a part interest from the applicant of the basic application filed in Japan and is an assignee of the basic applicants in respect of the application filed in the United States of America.

The basic applications listed on the Patent Request are the first applications made in Convention countries in respect of the invention.

Kubota Corporation is the depositor of the following deposits with the National Institute of Bioscience and Human-Technology, of Agency of Industrial Science and Technology, Ministry of International Trade and Industry, 1-3 Higashi 1-chome, Yatabe-machi, Tsukuba-gun, Ibaragi-ken, Japan. Mycogen Corporation has the consent of Kubota Corporation to rely on the following deposits:

Microorganism	Deposit Date	Accession No.
<i>Bacillus thuringiensis</i> serovar japonensis strain Buibui	26 June 1991	FERM BP-3465
<i>Escherichia coli</i> KBR9207	13 July 1992	FERM BP-3929

Dated 25 June 1996



John David O'Connor



AU9224116

(12) PATENT ABRIDGMENT (11) Document No. AU-B-24116/92
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 675628

- (54) Title
NOVEL MICROORGANISM AND INSECTICIDE
- (51)^s International Patent Classification(s)
C12N 015/32 A01N 063/02 C12N 001/21 C12N 005/10
C12N 015/82 C12P 021/02
- (21) Application No. : 24116/92 (22) Application Date : 31.07.92
- (87) PCT Publication Number : WO93/03154
- (30) Priority Data
- (31) Number (32) Date (33) Country
3-193810 02.08.91 JP JAPAN
915203 23.07.92 US UNITED STATES OF AMERICA
- (43) Publication Date : 02.03.93
- (44) Publication Date of Accepted Application : 13.02.97
- (71) Applicant(s)
MYCOGEN CORPORATION; KUBOTA CORPORATION
- (72) inventor(s)
MICHIO OHBA; HIDENORI IWAHANA; RYOICHI SATO; NOBUKAZU SUZUKI; KATSUTOSHI
OGIWARA; KAZUNOBU SAKANAKA; HIDETAKA HORI; SHOUJI ASANO; TADAAKI KAWASUGI
- (74) Attorney or Agent
SPRUSON & FERGUSON , GPO Box 3898, SYDNEY NSW 2001
- (56) Prior Art Documents
AU 636633 59984/90 C12N 1/20 A01N 63/02
AU 626804 23651/88 C12N 15/00 15/32
AU 639788 77526/91 C12N 15/32
- (57)

(1) GENERAL INFORMATION:

- (i) APPLICANT: Ohba, Michio
Iwahana, Hidenori
Sato, Reiichi
Suzuki, Nobukazu
Ogiwara, Katsutoshi
Sakanaka, Kazunobu
Hori, Hidetaki
Asano, Shouji
Kawasugi, Tadaaki
- (ii) TITLE OF INVENTION: Novel Microorganism and Insecticide
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: David R. Saliwanchik
(B) STREET: 2421 N.W. 41st Street, Suite A-1
(C) CITY: Gainesville
(D) STATE: FL
(E) COUNTRY: US
(F) ZIP: 32606
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Saliwanchik, David R.
(B) REGISTRATION NUMBER: 31,794
(C) REFERENCE/DOCKET NUMBER: M/K 301

(11) AU-B-24116/92
(10) 675628

-2-

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 904-375-8100
(B) TELEFAX: 904-372-5800

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3797 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Bacillus thuringiensis*
(B) STRAIN: japonensis
(C) INDIVIDUAL ISOLATE: Buibui

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 187..3636

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
AATTCTAATG ACACAGTAGA ATATTTTAA AATAAAGATG GAAGGGGGAA TATGAAAAAA      60
ATATAATCAT AAGAGTCATA CAAAAAGATT GTATGTTAAA ACAAAAAAAT CCTGTAGGAA      120
TAGGGGTTTA AAAGCAATCA TTTGAAAAGA TAGTTATATT AAATTGTATG TATAGGGGGA      180

AAAAAG ATG AGT CCA AAT AAT CAA AAT GAG TAT GAA ATT ATA GAT GCT      228
Met Ser Pro Asn Asn Gln Asn Glu Tyr Glu Ile Ile Asp Ala
      1           5           10

TTA TCA CCC ACT TCT GTA TCC GAT AAT TCT ATT AGA TAT CCT TTA GCA      276
Leu Ser Pro Thr Ser Val Ser Asp Asn Ser Ile Arg Tyr Pro Leu Ala
      15           20           25           30

TTA TCA CCC ACT TCT GTA TCC GAT AAT TCT ATT AGA TAT CCT TTA GCA      276
Leu Ser Pro Thr Ser Val Ser Asp Asn Ser Ile Arg Tyr Pro Leu Ala
      15           20           25           30

AAC GAT CAA ACG AAC ACA TTA CAA AAC ATG AAT TAT AAA GAT TAT CTG      324
Asn Asp Gln Thr Asn Thr Leu Gln Asn Met Asn Tyr Lys Asp Tyr Leu
      35           40           45

AAA ATG ACC GAA TCA ACA AAT GCT GAA TTG TCT CGA AAT CCC GGG ACA      372
Lys Met Thr Glu Ser Thr Asn Ala Glu Leu Ser Arg Asn Pro Gly Thr
      50           55           60

TTT ATT AGT GCG CAG GAT GCG GTT GGA ACT GGA ATT GAT ATT GTT AGT      420
Phe Ile Ser Ala Gln Asp Ala Val Gly Thr Gly Ile Asp Ile Val Ser
      65           70           75

ACT ATA ATA AGT GGT TTA GGG ATT CCA GTG CTT GGG GAA GTC TTC TCA      468
Thr Ile Ile Ser Gly Leu Gly Ile Pro Val Leu Gly Glu Val Phe Ser
      80           85           90

ATT CTG GGT TCA TTA ATT GGC TTA TTG TGG CCG TCA AAT AAT GAA AAT      516
Ile Leu Gly Ser Leu Ile Gly Leu Leu Trp Pro Ser Asn Asn Glu Asn
      95           100           105           110

GTA TGG CAA ATA TTT ATG AAT CGA GTG GAA GAG CTA ATT GAT CAA AAA      564
Val Trp Gln Ile Phe Met Asn Arg Val Glu Glu Leu Ile Asp Gln Lys
      115           120           125

ATA TTA GAT TCT GTA AGA TCA AGA GCC ATT GCA GAT TTA GCT AAT TCT      612
Ile Leu Asp Ser Val Arg Ser Arg Ala Ile Ala Asp Leu Ala Asn Ser
      130           135           140

AGA ATA GCT GTA GAG TAC TAT CAA AAT GCA CTT GAA GAC TGG AGA AAA      660
Arg Ile Ala Val Glu Tyr Tyr Gln Asn Ala Leu Glu Asp Trp Arg Lys
      145           150           155

AAC CCA CAC AGT ACA CGA AGC GCA GCA CTT GTA AAG GAA AGA TTT GGA      708
Asn Pro His Ser Thr Arg Ser Ala Ala Leu Val Lys Glu Arg Phe Gly
      160           165           170

AAT GCA GAA GCA ATT TTA CGT ACT AAC ATG GGT TCA TTT TCT CAA ACG      756
Asn Ala Glu Ala Ile Leu Arg Thr Asn Met Gly Ser Phe Ser Gln Thr
      175           180           185           190
```

.../3

(11) AU-B-24116/92
(10) 675628

-3-

AAT Asn	TAT Tyr	GAG Glu	ACT Thr	CCA Pro 195	CTC Leu	TTA Leu	CCC Pro	ACA Thr	TAT Tyr 200	GCA Ala	CAG Gln	GCC Ala	GCC Ala	TCT Ser 205	CTG Leu	804
CAT His	TTG Leu	CTT Leu	GTA Val 210	ATG Met	AGG Arg	GAT Asp	GTT Val	CAA Gln 215	ATT Ile	TAC Tyr	GGG Gly	AAG Lys	GAA Glu 220	TGG Trp	GGA Gly	852
TAT Tyr	CCT Pro	CAA Gln 225	AAT Asn	GAT Asp	ATT Ile	GAC Asp	CTA Leu 230	TTT Phe	TAT Tyr	AAA Lys	GAA Glu	CAA Gln 235	GTA Val	TCT Ser	TAT Tyr	900
ACG Thr	GCT Ala 240	AGA Arg	TAT Tyr	TCC Ser	GAT Asp	CAT His 245	TGC Cys	GTC Val	CAA Gln	TGG Trp	TAC Tyr 250	AAT Asn	GCT Ala	GGT Gly	TTA Leu	948
AAT Asn 255	AAA Lys	TTA Leu	AGA Arg	GGA Gly	ACG Thr 260	GGT Gly	GCT Ala	AAG Lys	CAA Gln	TGG Trp 265	GTG Val	GAT Asp	TAT Tyr	AAT Asn	CGT Arg 270	996
TTC Phe	CGA Arg	AGA Arg	GAA Glu	ATG Met 275	AAT Asn	GTG Val	ATG Met	GTA Val	TTG Leu 280	GAT Asp	CTA Leu	GTT Val	GCA Ala	TTA Leu 285	TTT Phe	1044
CCA Pro	AAC Asn	TAC Tyr	GAT Asp 290	GCG Ala	CGT Arg	ATA Ile	TAT Tyr	CCA Pro 295	CTG Leu	GAA Glu	ACA Thr	AAT Asn	GCA Ala 300	GAA Glu	CTT Leu	1092
ACA Thr	AGA Arg	GAA Glu 305	ATT Ile	TTC Phe	ACA Thr	GAT Asp	CCT Pro 310	GTT Val	GGA Gly	AGT Ser	TAC Tyr	GTA Val 315	ACT Thr	GGA Gly	CAA Gln	1140
TCG Ser	AGT Thr 320	ACC Thr	CTT Leu	ATA Ile	TCT Ser	TGG Trp 325	TAC Tyr	GAT Asp	ATG Met	ATT Ile	CCA Pro 330	GCA Ala	GCT Ala	CTT Leu	CCT Pro	1188
TCA Ser 335	TTT Phe	TCA Ser	ACG Thr	CTC Leu	GAG Glu 340	AAC Asn	CTA Leu	CTT Leu	AGA Arg	AAA Lys 345	CCT Pro	GAT Asp	TTC Phe	TTT Phe	ACT Thr 350	1236
TTG Leu	CTG Leu	CAA Gln	GAA Glu	ATT Ile 355	AGA Arg	ATG Met	TAT Tyr	ACA Thr	AGT Ser 360	TTT Phe	AGA Arg	CAA Gln	AAC Asn	GGT Gly 365	ACG Thr	1284
ATT Ile	GAA Glu	TAT Tyr 370	TAT Tyr	AAT Asn	TAT Tyr	TGG Trp	GGA Gly 375	GGA Gln	CAA Gln	AGG Arg	TTA Leu	ACC Thr	CTT Leu 380	TCT Ser	TAT Tyr	1332
ATC Ile	TAT Tyr	GGT Gly 385	TCC Ser	TCA Ser	TTC Phe	AAT Asn	AAA Lys 390	TAT Tyr	AGT Ser	GGG Gly	GTT Val	CTT Leu 395	GCC Ala	GGT Gly	GCT Ala	1380
GAG Glu	GAT Asp 400	ATT Ile	ATT Ile	CCT Pro	GTG Val	GGT Gly 405	CAA Gln	AAT Asn	GAT Asp	ATT Ile	TAC Tyr 410	AGA Arg	GTT Val	GTA Val	TGG Trp	1428
ACT Thr 415	TAT Tyr	ATA Ile	GGA Gly	AGG Arg	TAC Thr 420	ACG Thr	AAT Asn	AGT Ser	CTG Leu	CTA Leu 425	GGA Gly	GTA Val	AAT Asn	CCA Pro	GTT Val 430	1476
ACT Thr	TTT Phe	TAC Tyr	TTC Phe	AGT Ser 435	AAT Asn	AAT Asn	ACA Thr	CAA Gln	AAA Lys 440	ACT Thr	TAT Tyr	TCG Ser	AAG Lys	CCA Pro 445	AAA Lys	1524
CAA Gln	TTC Phe	GCG Ala	GGT Gly 450	GGA Gly	ATA Ile	AAA Lys	ACA Thr	ATT Ile 455	GAT Asp	TCC Ser	GGC Gly	GAA Glu	GAA Glu 460	TTA Leu	ACT Thr	1572
TAC Tyr	GAA Glu	AAT Asn 465	TAT Tyr	CAA Gln	TCT Ser	TAT Tyr	AGT Ser 470	CAC His	AGG Arg	GTA Val	AGT Ser	TAC Tyr 475	ATT Ile	ACA Thr	TCT Ser	1620
TTT Phe	GAA Glu 480	ATA Ile	AAA Lys	AGT Ser	ACC Thr	GGT Gly 485	GGT Gly	ACA Thr	GTA Val	TTA Leu	GGA Gly 490	GTA Val	GTT Val	CCT Pro	ATA Ile	1668
TTT Phe 495	GGT Gly	TGG Trp	ACG Thr	CAT His	AGT Ser 500	AGT Ser	GCC Ala	AGT Ser	CGC Arg	AAT Asn 505	AAC Asn	TTT Phe	ATT Ile	TAC Tyr	GCA Ala 510	1716
ACA Thr	AAA Lys	ATC Ile	TCA Ser	CAA Gln 515	ATC Ile	CCA Pro	ATC Ile	AAT Asn	AAA Lys 520	GCA Ala	AGT Ser	AGA Arg	ACT Thr	AGC Ser 525	GGT Gly	1764

(11) AU-B-24116/92
(10) 675628

- 4 -

GGA Gly	GCG Ala	GTT Val	TGG Trp 530	AAT Asn	TTC Phe	CAA Gln	GAA Glu	GGT Gly 535	CTA Leu	TAT Tyr	AAT Asn	GGA Gly	GGA Gly 540	CCT Pro	GTA Val	1812
ATG Met	AAA Lys	TTA Leu 545	TCT Ser	GGG Gly	TCT Ser	GGT Gly	TCC Ser 550	CAA Gln	GTA Val	ATA Ile	AAC Asn	TTA Leu 555	AGG Arg	GTC Val	GCA Ala	1860
ACA Thr	GAT Asp 560	GCA Ala	AAG Lys	GGA Gly	GCA Ala	AGT Ser 565	CAA Gln	AGA Arg	TAT Tyr	CGT Arg	ATT Ile 570	AGA Arg	ATC Ile	AGA Arg	TAT Tyr	1908
GCC Ala 575	TCT Ser	GAT Asp	AGA Arg	GCG Ala	GGT Gly 580	AAA Lys	TTT Phe	ACG Thr	ATA Ile	TCT Ser 585	TCC Ser	AGA Arg	TCT Ser	CCA Pro	GAG Glu 590	1956
AAT Asn	CCT Pro	GCA Ala	ACC Thr 595	TAT Tyr 595	TCA Ser	GCT Ala	TCT Ser	ATT Ile	GCT Ala 600	TAT Tyr	ACA Thr	AAT Asn	ACT Thr	ATG Met 605	TCT Ser	2004
ACA Thr	AAT Asn	GCT Ala	TCT Ser 610	CTA Leu	ACG Thr	TAT Tyr	AGT Ser	ACT Thr 615	TTT Phe	GCA Ala	TAT Tyr	GCA Ala	GAA Glu 620	TCT Ser	GGC Gly	2052
CCT Pro	ATA Ile	AAC Asn 625	TTA Leu	GGG Gly	ATT Ile	TCG Ser	GGA Gly 630	AGT Ser	TCA Ser	AGG Arg	ACT Thr	TTT Phe 635	GAT Asp	ATA Ile	TCT Ser	2100
ATT Ile	ACA Thr 640	AAA Lys	GAA Glu	GCA Ala	GGT Gly	GCT Ala 645	GCT Ala	AAC Asn	CTT Leu	TAT Tyr	ATT Ile 650	GAT Asp	AGA Arg	ATT Ile	GAA Glu	2148
TTT Phe 655	ATT Ile	CCA Pro	GTT Val	AAT Asn 660	ACG Thr 660	TTA Leu	TTT Phe	GAA Glu	GCA Ala	GAA Glu 665	GAA Glu	GAC Asp	CTA Leu	GAT Asp	GTG Val 670	2196
GCA Ala	AAG Lys	AAA Lys	GCT Ala 675	GTG Val 675	AAT Asn	GGC Gly	TTG Leu	TTT Phe	ACG Thr 680	AAT Asn	GAA Glu	AAA Lys	GAT Asp 685	GCC Ala 685	TTA Leu	2244
CAG Gln	ACA Thr	AGT Ser	GTA Val 690	ACG Thr	GAT Asp	TAT Tyr	CAA Gln	GTC Val 695	AAT Asn	CAA Gln	GCG Ala	GCA Ala	AAC Asn 700	TTA Leu	ATA Ile	2292
GAA Glu	TGC Cys	CTA Leu 705	TCC Ser	GAT Asp	GAG Glu	TTA Leu	TAC Tyr 710	CCA Pro	AAT Asn	GAA Glu	AAA Lys	CGA Arg 715	ATG Met	TTA Leu	TGG Trp	2340
GAT Asp	GCA Ala 720	GTG Val	AAA Lys	GAG Glu	GCG Ala	AAA Lys 725	CGA Arg	CTT Leu	GTT Val	CAG Gln	GCA Ala 730	CGT Arg	AAC Asn	TTA Leu	CTC Leu	2388
CAA Gln 735	GAT Asp	ACA Thr	GGC Gly	TTT Phe 740	AAT Asn	AGG Arg	ATT Ile	AAT Asn	GGA Gly 745	GAA Glu 745	AAC Asn	GGA Gly	TGG Trp	ACG Thr 750	GGA Gly 750	2436
AGT Ser	ACG Thr	GGA Gly	ATC Ile	GAG Glu 755	GTT Val	GTG Val	GAA Glu	GGA Gly	GAT Asp 760	GTT Val	CTG Leu	TTT Phe	AAA Lys 765	GAT Asp 765	CGT Arg	2484
TCG Ser	CTT Leu	CGT Arg	TTG Leu 770	ACA Thr	AGT Ser	GCG Ala	AGA Arg	GAG Glu 775	ATT Ile	GAT Asp	ACA Thr	GAA Glu 780	ACA Thr 780	TAT Tyr	CCA Pro	2532
ACG Thr	TAT Tyr 785	CTC Leu	TAT Tyr	CAA Gln	CAA Gln	ATA Ile	GAT Asp 790	GAA Glu	TCG Ser	CTT Leu	TTA Leu	AAA Lys 795	CCA Pro	TAT Tyr	ACA Thr	2580
AGA Arg	TAT Tyr 800	AAA Lys	CTA Leu	AAA Lys	GGT Gly	TTT Phe 805	ATA Ile	GGA Gly	AGT Ser	AGT Ser	CAA Gln 810	GAT Asp	TTA Leu	GAG Glu	ATT Ile	2628
AAA Lys 815	TTA Leu	ATA Ile	CGT Arg	CAT His 820	CGG Arg	GCA Ala	AAT Asn	CAA Gln	ATC Ile	GTC Val 825	AAA Lys	AAT Asn	GTA Val	CCA Pro	GAT Asp 830	2676
AAT Asn	CTC Leu	TTG Leu	CCA Pro 835	GAT Asp 835	GTA Val	GCG Arg	CCT Pro	GTC Val	AAT Asn 840	TCT Ser	TGT Cys	GGT Gly	GGA Gly	GTC Val 845	GAT Asp	2724
CGC Arg	TGC Cys	AGT Ser	GAA Glu 850	CAA Gln	CAG Gln	TAT Tyr	GTA Val	GAC Asp 855	GCG Ala	AAT Asn	TTA Leu	GCA Ala	CTC Leu 860	GAA Glu	AAC Asn	2772
AAT Asn	GGA Glu 865	GAA Glu 865	AAT Asn	GGA Gly	AAT Asn	ATG Met	TCT Ser 870	TCT Ser	GAT Asp	TCC Ser	CAT His	GCA Ala 875	TTT Phe	TCT Ser	TTC Phe	2820

.../5

(11) AU-B-24116/92

-5-

(10) 675628

CAT His	ATT Ile	GAT Asp	ACG Thr	GGT Gly	GAA Glu	ATA Ile	GAT Asp	TTG Leu	AAT Asn	GAA Glu	AAT Asn	ACA Thr	GGA Gly	ATT Ile	TGG Trp	2868	
ATC Ile	GTA Val	TTT Phe	AAA Lys	ATT Ile	CCG Pro	ACA Thr	ACA Thr	AAT Asn	GGA Gly	AAC Asn	GCA Ala	ACA Thr	CTA Leu	GGA Gly	AAT Asn	2916	
CTT Leu	GAA Glu	TTT Phe	GTA Val	GAA Glu	GAG Glu	GGG Gly	CCA Pro	TTG Leu	TCA Ser	GGG Gly	GAA Glu	ACA Thr	TTA Leu	GAA Glu	TGG Trp	2964	
GCC Ala	CAA Gln	CAA Gln	CAA Gln	GAA Glu	CAA Gln	CAA Gln	TGG Trp	CAA Gln	GAC Asp	AAA Lys	ATG Met	GCA Ala	AGA Arg	AAA Lys	CGT Arg	3012	
GCA Ala	GCA Ala	TCA Ser	GAA Glu	AAA Lys	ACA Thr	TAT Tyr	TAT Tyr	GCA Ala	GCA Ala	AAG Lys	CAA Gln	GCC Ala	ATT Ile	GAT Asp	CGT Arg	3060	
TTA Leu	TTC Phe	GCA Ala	GAT Asp	TAT Tyr	CAA Gln	GAC Asp	CAA Gln	AAA Lys	CTT Leu	AAT Asn	TCT Ser	GGT Gly	GTA Val	GAA Glu	ATG Met	3108	
TCA Ser	GAT Asp	TTG Leu	TTG Leu	GCA Ala	GCC Ala	CAA Gln	AAC Asn	CTT Leu	GTA Val	CAG Gln	TCC Ser	ATT Ile	CCT Pro	TAC Tyr	GTA Val	3156	
TAT Tyr	AAT Asn	GAT Asp	GCG Ala	TTA Leu	CCG Pro	GAA Glu	ATC Ile	CCT Pro	GGA Gly	ATG Met	AAC Asn	TAT Tyr	ACG Thr	AGT Thr	TTT Phe	3204	
ACA Thr	GAG Glu	TTA Leu	ACA Thr	AAT Asn	AGA Arg	CTC Leu	CAA Gln	CAA Gln	GCA Ala	TGG Trp	AAT Asn	TTG Leu	TAT Tyr	GAT Asp	CTT Leu	3252	
CAA Gln	AAC Asn	GCT Ala	ATA Ile	CCA Pro	AAT Asn	GGA Gly	GAT Asp	TTT Phe	CGA Arg	AAT Asn	GGA Gly	TTA Leu	AGT Ser	AAT Asn	TGG Trp	3300	
AAT Asn	GCA Ala	ACA Thr	TCA Ser	GAT Asp	GTA Val	AAT Asn	GTG Val	CAA Gln	CAA Gln	CTA Leu	AGC Ser	GAT Asp	ACA Thr	TCT Ser	GTC Val	3348	
CTT Leu	GTC Val	ATT Ile	CCA Pro	AAC Asn	TGG Trp	AAT Asn	TCT Ser	CAA Gln	GTG Val	TCA Ser	CAA Gln	CAA Gln	TTT Phe	ACA Thr	GTT Val	3396	
CAA Gln	CCG Pro	AAT Asn	TAT Tyr	AGA Arg	TAT Tyr	GTG Val	TTA Leu	CGT Arg	GTC Val	ACA Thr	GCG Ala	AGA Arg	AAA Lys	GAG Glu	GGA Gly	3444	
GTA Val	GGA Gly	GAC Asp	GGA Gly	TAT Tyr	GTG Val	ATC Ile	ATC Ile	CGT Arg	GAT Asp	GGT Gly	GCA Ala	AAT Asn	CAG Gln	ACA Thr	GAA Glu	3492	
ACA Thr	CTC Leu	ACA Thr	TTT Phe	AAT Asn	ATA Ile	TGT Cys	GAT Asp	GAT Asp	GAT Asp	ACA Thr	GGT Gly	GTT Val	TTA Leu	TCT Ser	ACT Thr	3540	
GAT Asp	CAA Gln	ACT Thr	AGC Ser	TAT Tyr	ATC Ile	ACA Thr	AAA Lys	ACA Thr	GTG Val	GAA Glu	TTC Phe	ACT Thr	CCA Pro	TCT Ser	ACA Thr	3588	
GAG Glu	CAA Gln	GTT Val	TGG Trp	ATT Ile	GAC Asp	ATG Met	AGT Ser	GAG Glu	ACC Thr	GAA Glu	GTG Val	TAT Tyr	TCA Ser	ACA Thr	TAGAAAGTGT	3643	
AGA Gln	ACT Thr	CGTG Gln	TTAGA Gln	AAGA Gln	AGG Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	AGT Gln	3703
GGT Gln	TTT Phe	TCT Ser	TTA Leu	GAG Glu	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	AGT Ser	3763
TAT Thr	TCT Ser	CAA Gln	AAT Asn	ATC Ile	ACA Thr	CAAG Gln	GTT Trp	TAT Tyr	AAAT Asn	GTT Trp	TGA Cys	ATG Met	AGT Ser	AGT Ser	AGT Ser	AGT Ser	3797

(11) AU-B-24116/92
(10) 675628

-6-

Claim

1. A biologically pure culture of *Bacillus thuringiensis serovar japonensis* variety *Buibui* (FERM BP-3465).

2. A nucleotide sequence which codes for a toxin having activity against coleopterans wherein said nucleotide sequence codes for the amino acid sequence in SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2, comprises the sequence of SEQ ID NO. 1 or a part of the sequence of SEQ ID NO. 1 that encodes a protein toxic to coleopterans, or is sufficiently homologous to the sequence of SEQ ID NO. 1 to hybridise with the sequence of SEQ ID NO. 1 under high stringency conditions.

5. A substantially pure coleopteran-active toxin comprising the amino acid sequence of SEQ ID NO. 2 or an equivalent amino acid sequence having coleopteran activity and at least 75% homology with the amino acid sequence of SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 15/32, A01N 63/02 C12P 21/02, C12N 15/82, 1/21 // (C12N 1/21, C12R 1:19)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/03154 (43) International Publication Date: 18 February 1993 (18.02.93)</p>
<p>(21) International Application Number: PCT/US92/06404 (22) International Filing Date: 31 July 1992 (31.07.92) (30) Priority data: 193810/91 2 August 1991 (02.08.91) JP 915,203 23 July 1992 (23.07.92) US (71) Applicants: MYCOGEN CORPORATION [US/US]; 5451 Oberlin Drive, San Diego, CA 92121 (US). KUBOTA CORPORATION [JP/JP]; 1-3, Nihombashi-Muromachi 3-chome, Chuo-ku, Tokyo 103 (JP). (72) Inventors: OHBA, Michio ; 4-12-1103, Higashi-ku, Hakozaki 5-chome, Fukuoka City, Fukuoka 812 (JP). IWAHANA, Hidenori ; 1521-44, Nougayamachi, Machida City, Tokyo 194-01 (JP). SATO, Ryoichi ; Koganei Koumuin Juutaku, 2-2237, Nukui Kitamachi 3-chome, Kohanei City, Tokyo 184 (JP). SUZUKI, Nobukazu ; 4-102, Kubota Ryuugasaki Haitsu, 6-1, Koshiha 4-chome, Ryuugasaki City, Ibaraki 301 (JP). OGIWARA, Katsutoshi ; 5-306, Kubota Ryuugakasi Haitsu, 6-1, Koshiha 4-chome, Ryuugasaki City, Ibaraki 301 (JP). SAKANAKA, Kazunobu ; 4-102, Kubota Ryuugasaki Haitsu, 6-1, Koshiha 4-chome, Ryuugasaki City, Ibaraki 301 (JP). HORI, Hidetaka ; 1108-2, Daigiri, Fujisawa City, Kanagawa 251 (JP). ASANO, Shouji ; 134-4, Kariya Chou 1-chome, Ushiku City, Ibaraki 300-12 (JP). KAWASUGI, Tadaaki ; 356-190, Ushiku Chou, Ushiku City, Ibaraki 300-12 (JP).</p>	<p>(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik & Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL 32606 (US). (81) Designated States: AU, CA, HU, KR, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE) Published <i>With international search report.</i></p>	
<p>(54) Title: NOVEL MICROORGANISM AND INSECTICIDE</p>		
<p>(57) Abstract <i>Bacillus thuringiensis</i> serovar <i>japonensis</i> strain <i>Buibui</i> (FERM BP-3465) belonging to <i>Bacillus thuringiensis</i> serovar <i>japonensis</i> and capable of producing insecticidal toxin proteins to kill coleopterous larvae, and an insecticide containing, as an effective ingredient, the toxin proteins produced.</p>		

675628

DESCRIPTIONNOVEL MICROORGANISM AND INSECTICIDE

5

Background of the Invention

Field of the Invention. This invention relates to a novel microorganism belonging to *Bacillus thuringiensis* serovar *japonensis*, to an insecticide derived from this novel microorganism, and to DNA coding for the insecticide.

10 Description of the Related Art. The reported activity spectrum of *B.t.* covers insect species within the order Lepidoptera, many of which are major pests in agriculture and forestry. The activity spectrum also includes the insect order Diptera, which includes mosquitos and black flies. See Couch, T.L. (1980) "Mosquito Pathogenicity of *Bacillus thuringiensis* var. *israelensis*," *Developments in Industrial Microbiology* 22:61-76; Beegle, C.C., (1978) "Use of Entomogenous Bacteria in Agroecosystems," *Developments in Industrial Microbiology* 20:97-104.

15 Krieg *et al.* (1983) *Z. ang. Ent.* 96:500-508, describe a *B.t.* isolate named *Bacillus thuringiensis* var. *tenebrionis*, which is reportedly active against two beetles in the order Coleoptera. These are the Colorado potato beetle, *Leptinotarsa decemlineata*, and *Agelastica alni*.

20 In European Patent Application 0 202 739 there is disclosed a novel *B.t.* isolate active against Coleoptera. It is known as *B. thuringiensis* var. *san diego* (*B.t.s.d.*). U.S. Patent No. 4,966,765 discloses the coleopteran-active *Bacillus thuringiensis* isolate *B.t.* PS86B1. European Patent Application 0 337 604 also discloses a novel *B.t.* isolate active against Coleoptera.

25 Coleopteran-active *B.t.* strains can be used to control foliar-feeding beetles. The Colorado potato beetle (*Leptinotarsa decemlineata*), for example, is susceptible to the delta-endotoxin of *B.t.s.d.* and larvae are killed upon ingesting a sufficient dose of spore/crystal preparation on treated foliage. Strain cells among *Bacillus thuringiensis* serovar *japonensis* are known to produce insecticidal proteins that kill lepidopteran larvae.

30 *japonensis* are known to produce toxin proteins other than the insecticidal proteins that kill lepidopterous larvae. Thus, no such strain cells have been available for

use as an insecticide to kill insects other than lepidopterans. Furthermore, *Bacillus thuringiensis san diego* and *Bacillus thuringiensis tenebrionis* have no insecticidal effect on larvae of *Anomala cuprea* Hope, which are very destructive to firewood, taro, sweet potato, peanut, and the like.

5 The current inventors have found a new type of microorganism belonging to *Bacillus thuringiensis* serovar *japonensis* that produces insecticidal proteins to kill coleopterous larvae as distinct from lepidopterous larvae.

Brief Summary of the Invention

10 The subject invention concerns a novel *Bacillus thuringiensis* (*B.t.*) isolate. The novel *B.t.* isolate, known as *Bacillus thuringiensis* serovar *japonensis* strain *Buibui* (hereinafter referred to as "*B.t. Buibui*"), has been found to be active against coleopteran pests including the Japanese beetle. A novel δ -endotoxin gene of the invention encodes an \approx 130 kDa protein. The nucleotide sequence of
15 this gene is shown in SEQ ID NO. 1. The predicted amino acid sequence of the toxin is shown in SEQ ID NO. 2.

 The subject invention also includes variants of *B.t. Buibui* which have substantially the same pesticidal properties as *B.t. Buibui*. These variants would include mutants. Procedures for making mutants are well known in the
20 microbiological art. Ultraviolet light and nitrosoguanidine are used extensively toward this end.

 Further, the invention also includes the treatment of substantially intact *B.t.* cells, and recombinant cells containing a gene of the invention, to prolong the pesticidal activity when the substantially intact cells are applied to the
25 environment of a target pest. Such treatment can be by chemical or physical means, or a combination of chemical or physical means, so long as the technique does not deleteriously affect the properties of the pesticide, nor diminish the cellular capability in protecting the pesticide. The treated cell acts as a protective coating for the pesticidal toxin. The toxin becomes available to act as such upon
30 ingestion by a target insect.

Brief Description of the Drawings

Figure 1 is a graph showing growth curves of *B.t. Buibui*. The number of colonies produced by splaying the cells in the following agar culture media of the petri dish is measured. -●- LB medium; -○- NB medium; -Δ- NYS medium.

5 Figure 2 is a graph showing growth curves of *B.t. Buibui*. The increase of the number of cells is shown by the absorptive increase of media at 660 nm. -●- LB medium; -○- NB medium; -Δ- NYS medium.

10 Figure 3 is a photograph showing colonies of *B.t. Buibui* in LB culture medium. The colonies of *Buibui* strain were cultured in the LB agar culture media for 72 hours after being cultured in the LB culture media for 8 hours.

Figure 4 is a photograph showing colonies of *B.t. Buibui* in various culture media. The colonies of *Buibui* strain were cultured in the respective agar culture media for 72 hours after being cultured in the LB, NB, and NYS culture media for 8 hours and 14 hours.

15 Figure 5 is a photograph of *japonensis* strain taken with a scanning electron microscope. The dark arrows show crystals of toxin proteins. The elliptic members having wrinkled surfaces are spores.

20 Figure 6 is a photograph of *B.t. Buibui* taken with the scanning electron microscope. The dark arrows show crystals of toxin proteins. The elliptic members having wrinkled surfaces are spores.

25 Figure 7 is a photograph showing sodium dodecyl sulfate polyacrylamide gel electrophoresis. Lane 1 is a molar weight marker. Lane 2 shows toxin proteins produced by *japonensis* strain (5 μ l). Lane 3 shows toxin proteins produced by *japonensis* strain (10 μ l). Lane 4 shows toxin proteins produced by *japonensis* strain (15 μ l). Lane 5 shows toxin proteins produced by *japonensis* strain (20 μ l). Lane 6 shows toxin proteins produced by *Buibui* strain (5 μ l). Lane 7 shows toxin proteins produced by *Buibui* strain (10 μ l). Lane 8 shows toxin proteins produced by *Buibui* strain (5 μ l). Lane 9 is a molar weight marker.

30 Figure 8 is a graph showing time-dependent death curves of larvae of *Anomala cuprea* Hope. — 12.5 μ g/ml; ----- 1.25 μ g/ml; 0.125 μ g/ml; — control.

Brief Description of the Sequences

SEQ ID NO. 1 is the composite nucleotide and amino acid sequence of the novel gene of the invention.

SEQ ID NO. 2 is the predicted amino acid sequence of the toxin.

5

Disclosure of the Invention

According to a first embodiment of this invention there is provided a biologically pure culture of *Bacillus thuringiensis serovar japonensis* variety *Buibui* (FERM BP-3465).

According to a second embodiment of this invention there is provided a nucleotide sequence which codes for a toxin having activity against coleopterans wherein said
10 nucleotide sequence codes for the amino acid sequence in SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2, comprises the sequence of SEQ ID NO. 1 or a part of the sequence of SEQ ID NO. 1 that encodes a protein toxic to coleopterans, or is sufficiently homologous to the sequence of SEQ ID NO. 1 to hybridise with the sequence of SEQ ID NO. 1 under high stringency conditions.

15

According to a third embodiment of this invention there is provided a substantially pure coleopteran-active toxin comprising the amino acid sequence of SEQ ID NO. 2 or an equivalent amino acid sequence having coleopteran activity and at least 75% homology with the amino acid sequence of SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2.

20

Detailed Description of the Invention

The subject invention pertains to a novel strain of *Bacillus thuringiensis* which has the highly advantageous property of expressing at least one endotoxin which is toxic to coleopterans. The novel microorganism has been designated *Bacillus thuringiensis serovar japonensis strain Buibui* (hereinafter referred to as "*B.t. Buibui*"). The subject
25 invention further pertains to insecticidal toxin obtainable from *B.t. Buibui* as well as DNA coding for said insecticide. Also disclosed and claimed are microorganisms, other than *Bacillus thuringiensis*, which have been transformed with *B.t. Buibui* DNA so that said transformed microbes express a coleopteran-active toxin. A further aspect of the subject invention is the use of a toxin of the subject invention, or a transformed host-expressing a
30 toxin, to control coleopteran pests. Yet a further aspect of the subject invention pertains to plants transformed with a *B.t. Buibui* DNA coding for toxin active against coleopteran pests.

Novel microorganisms according to the present invention, have been deposited internationally, pursuant to the Treaty of Budapest, with the Fermentation Research

Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, which is a recognised international depository organisation.

Culture	Deposit No.	Deposit Date
<i>Bacillus thuringiensis</i> serovar <i>japonensis</i> strain Buibui	FERM BP-3465	June 26, 1991
<i>Escherichia coli</i> KBR9207	FERM BP-3929	July 13, 1992

The subject cultures have been deposited under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of a deposit, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the cultures. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposits. All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them.

The invention also includes variants of the subject isolates which variants have genes encoding all or part of a toxin of the invention. Such microbial variants may be isolated or they can be made by techniques well known to persons skilled in the art. For example, UV irradiation can be used to prepare variants of host organisms. Likewise, such variants may include asporogenous host cells which also can be prepared by procedures well known in the art. For example, an asporogenous mutant can be obtained through ethylmethane sulfonate (EMS) mutagenesis of a novel isolate. A small percentage of the asporogenous mutants will remain intact and not lyse for extended fermentation periods; these strains are designated lysis minus (-). Lysis minus strains can be identified by screening asporogenous mutants in shake flask media and selecting those mutants that are still intact and contain toxin crystals at the end of the fermentation. Lysis minus

strains are suitable for a cell fixation process that yield a protected, encapsulated toxin protein.

To prepare a phage resistant variant of said asporogenous mutant, an aliquot of the phage lysate is spread onto nutrient agar and allowed to dry. An aliquot of the phage sensitive bacterial strain is then plated directly over the dried lysate and allowed to dry. The plates are incubated at 30°C. The plates are incubated for 2 days and, at that time, numerous colonies could be seen growing on the agar. Some of these colonies are picked and subcultured onto nutrient agar plates. These apparent resistant cultures are tested for resistance by cross streaking with the phage lysate. A line of the phage lysate is streaked on the plate and allowed to dry. The presumptive resistant cultures are then streaked across the phage line. Resistant bacterial cultures show no lysis anywhere in the streak across the phage line after overnight incubation at 30°C. The resistance to phage is then reconfirmed by plating a lawn of the resistant culture onto a nutrient agar plate. The sensitive strain is also plated in the same manner to serve as the positive control. After drying, a drop of the phage lysate is plated in the center of the plate and allowed to dry. Resistant cultures showed no lysis in the area where the phage lysate has been placed after incubation at 30°C for 24 hours.

The variants can also be made using ultraviolet light and nitrosoguanidine by procedures well known in the art.

The novel microorganism, *B.t. Buibui*, specifically exemplified according to the present invention has the following characteristics:

1. Growth in Different Culture Media. This microorganism may be grown and the toxin proteins may be produced in all types of media that can be used for culturing ordinary bacteria. As shown in Figures 1 and 2, the microorganism showed ordinary growth patterns in typical culture media such as NYS, L-broth, and bouillon media. That is, the number of cells began to increase logarithmically after lapse of several hours, and the increase stopped upon lapse of 24 hours. Toxins appeared slightly after the increase in the number of cells. The quantity of toxins, when measured in the main band 130 kDa, was 200 to 300 µg/ml medium.

2. Morphological Characteristics. As shown in Figures 3 and 4, the colonies produced have surface gloss on an agar medium, and spread thinly over the agar surfaces without swelling. Peripheral roughs show characteristics of ordinary *Bacillus* cells. The color of the colonies is light beige.

5 When observed through a scanning electron microscope, both *Bacillus thuringiensis* serovar *japonensis* and *Bacillus thuringiensis* serovar *japonensis* strain *Buibui* show spherical crystal proteins. These are distinct from the bipyramid crystals commonly observed with other *B.t.* cells lethal to lepidopterous larvae.

10 3. Biochemical Appearance. The following tests have been conducted to evaluate the biochemical characteristics of *B.t. Buibui* as compared with conventional *japonensis* strains:

15 Test 1. Serotyping using antibodies produced against flagellar antigens: This is a method for identifying an unknown organism by employing an antibody active to the proteins of flagella of *Bacillus* organisms, and utilizing an antigen-antibody reaction in which the flagellar proteins of the unknown organism act as the antigens. *Japonensis* strain is a subspecies classified and recognized as H23 type (*J. Invertebr. Pathol.* 32:303-309, 1978; *J. Invertebr. Pathol.* 48:129-130, 1986). *B.t. Buibui* is reactive with H-antigen of *japonensis* strain. This property is serologically equivalent to that of *japonensis* strain. Thus, taxonomically, *B.t.*
20 *Buibui* belongs to the same subspecies as *japonensis* strain. Details of this test are as follows:

(1) Preparation of flagellar H-serum: Forty known types of H-antigen standard strains of *Bacillus thuringiensis* were used. Microorganisms having excellent mobility were selected by using a Craigie tube (0.5% semifluid agar medium), and formalin-killed organisms were prepared. Rabbits were
25 immunized with these organisms. H-serum was prepared by absorbing, from respective antisera, antibodies reactive to *Bacillus thuringiensis* cell antigens. The cell antigens were prepared by heating them to 100°C and separating the flagella.

(2) Identification of H-antigen: Serum types of H-antigen
30 were identified through agglutination reactions on slide glass (Ohba and Aizawa [1978] *J. Invertebr. Pathol.* 32:303-309). Agglutination values of H-serum were measured through *in vitro* agglutination reactions (Ohba and Aizawa. *supra*).

(3) Results: *Japonensis* strain was particularly agglutinated only by the serum for standard strain cells of serovar *japonensis* (H-antigen 23) among standard sera including 40 known types of flagellar antigens only. The agglutination value of *japonensis* H-serum for corresponding homo-antigens was 12,800-fold, and the agglutination value thereof for *Buibui* strain was 6,400-fold. The agglutination value of *B.t. Buibui* H-serum for homo was 12,800-fold and the agglutination value thereof for *japonensis* standard strain was 6,400-fold. Thus, the two strain cells are determined to be the same species.

Test 2. Insecticidal spectral of crystal proteins produced by *japonensis* strain and *B.t. Buibui*: As shown in Table 1, the insecticidal proteins produced by *B.t. Buibui* showed an insecticidal effect in a concentration of 0.125 to 12.5 $\mu\text{g/ml}$ on *Anomala cuprea* Hope, a coleopteran. However, the insecticidal proteins produced by the *japonensis* strain did not show an insecticidal effect even in a concentration of 100 $\mu\text{g/ml}$. As shown in Table 2, the insecticidal proteins produced by *japonensis* strain showed a high degree of activity with respect to larvae of lepidopterans such as *Plutella xylostella*, *Adoxophyes* sp., and *Bombyx mori*. However, the insecticidal proteins produced by *B.t. Buibui* showed little or a very low degree of activity. These results demonstrate that the two strains cannot be said to be the same strains. Furthermore, the observance of coleopteran activity, but no lepidopteran activity is quite surprising and unexpected.

Table 1. Insecticidal effects of *japonensis* strain and *B.t. Buibui* on *Anomala cuprea* Hope

Toxin dosage (μg 130 kDa protein/ml)	Death rates* (%)		
	7th day	14th day	22nd day
<i>B.t. Buibui</i> cells			
12.5	65	95	95
1.25	45	95	100
0.125	0	30	80
<i>Japonensis</i> strain cells			
100	0	0	0

*Number of samples = 20 larvae in the first instar.

Table 2. Insecticidal activities of *japonensis* strain and *Buibui* strain with respect to some lepidopterans.

Samples	Toxin dosage (μg 130 kDa protein/ml)	Death rates* (%)	
		<i>Buibui</i>	<i>japonensis</i>
<i>Plutella xylostella</i>	50	0	100
<i>Spodoptera litura</i>	500	0	---
	50	0	4
<i>Adoxophyes</i> sp.	50	6	47
<i>Spodoptera exigua</i>	50	10	3
<i>Bombyx mori</i>	50	0	70

*Number of samples = 50 larvae in the first to third instar.

Test 3. Electrophoresis of insecticidal proteins accumulating in the cells of *japonensis* strain and *B.t. Buibui*: *B.t. Buibui* produces, in the cells, spherical crystalline proteins as does *japonensis* strain (Figures 5 and 6). The crystalline proteins were isolated from the culture medium by a standard method (Goodman, N.S., R.J. Gottfried, M.J. Rogoff [1987] *J. Bacteriol.* 34:485). After purification, the proteins were dissolved in a 0.4 N alkali solution, and analyzed through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). As shown in Figure 7, *japonensis* strain has a main band at about 76 kDa, and a different band at 52 kDa. *B.t. Buibui* has a main band at about 130 kDa, and different bands at 52 kDa and 45 kDa. These electrophoresis patterns clearly show that the two types of crystalline proteins have different ingredients.

Test 4. Difference in adoptivity in culture media between *japonensis* strain and *B.t. Buibui*: As shown in Table 3, *japonensis* strain adopts glucose, salicin, and maltose, does not adopt mannose, and adopts cellobiose to a certain degree. *B.t. Buibui* can adopt all of these substances.

These features show that, taxonomically, *B.t. Buibui* is classified by serotype as *japonensis* strain, but clearly is a cell different from *japonensis* strain.

Table 3.

	<i>japonensis</i>	<i>Buibui</i>
Sugars		
	glucose	++
5	D-(+)-xylose	-
	D-(+)-arabinose	-
	mannitol	-
	galactose	-
	mannose	++
10	salicin	++
	sucrose	+ -
	D-(+)-cellobiose	++
	maltose	++
	lactose	-
15	acetoin	+
	urease	++

+++ = adopt very well; + = adopt well, + - = adopt; - = do not adopt

20 *B.t. Buibui* can be cultured using standard art media and fermentation techniques. Specific examples of fermentation media and techniques are provided in the examples which follow. Upon completion of the fermentation cycle, the bacteria can be harvested by first separating the *B.t.* spores and crystals from the fermentation broth by means well known in the art. The recovered *B.t.* spores
25 and crystals can be formulated into a wettable powder, liquid concentrate, granules, or other formulations by the addition of surfactants, dispersants, inert carriers and other components to facilitate handling and application for particular target pests. These formulation and application procedures are all well known in the art.

30 DNA containing the toxin gene from *B.t. Buibui* can be purified from *E. coli* KBR9207 by standard procedures well known in the art. The toxin gene can be excised from the plasmid DNA by restriction enzyme digestion. This subject invention pertains not only to the specific DNA sequence shown in SEQ ID NO. 1, but also to variations of this sequence which code for an amino acid sequence

having activity against coleopteran characteristics of the toxin produced by *B.t. Buibui*. These DNA sequences would be expected to have a high degree of homology and, for example, would be expected to hybridize with each other and/or common probes or primers under high stringency conditions. Similarly, the subject invention pertains not only to the protein having the amino acid sequence shown in SEQ ID NO. 2, but also to equivalent toxins having the same or similar biological activity of the toxin shown in SEQ ID NO. 2. These equivalent toxins may have amino acid homology with the toxin disclosed and claimed herein. This amino acid homology will typically be greater than 50%, preferably be greater than 75%, and most preferably be greater than 90%. The amino acid homology will be highest in certain critical regions of the toxin which account for biological activity or are involved in the determination of three-dimensional configuration which ultimately is responsible for the biological activity. In this regard, certain amino acid substitutions are acceptable and can be expected if these substitutions are in regions which are not critical to activity or are conservative amino acid substitutions which do not affect the three-dimensional configuration of the molecule. For example, amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution does not materially alter the biological activity of the compound. Table 4 provides a listing of examples of amino acids belonging to each class.

Table 4

Class of Amino Acid	Examples of Amino Acids
Nonpolar	Ala, Val, Leu, Ile, Pro, Met, Phe, Trp
Uncharged Polar	Gly, Ser, Thr, Cys, Tyr, Asn, Gln
Acidic	Asp, Glu
Basic	Lys, Arg, His

In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the biological activity of the toxin.

5 The genes and toxins according to the subject invention include not only the full length sequences disclosed herein but also fragments of these sequences, or fusion proteins, which retain the characteristic coleopteran activity of the toxins specifically exemplified herein.

10 It should be apparent to a person skilled in this art that genes coding for coleopteran-active toxins can be identified and obtained through several means. The specific genes may be obtained from a culture depository as disclosed herein. Alternatively, these genes, or portions thereof, may be constructed synthetically, for example, by use of a gene machine. Variations of these genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as *Bal31* or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which code for active fragments may be obtained using a variety of other restriction enzymes. Proteases may be used to directly obtain active fragments of these toxins.

20 DNA of the subject invention, which codes for coleopteran-active toxin, can be introduced into a wide variety of microbial and plant hosts. Expression of the DNA results, directly or indirectly, in the production and maintenance of the pesticide. With suitable hosts, e.g., *Pseudomonas*, the microbes can be applied to the situs of coleopteran insects where they will proliferate and be ingested by the insects. The result is a control of the unwanted insects. Alternatively, a microbe hosting the toxin-coding DNA can be treated under conditions that prolong the activity of the toxin produced in the cell. The treated cell then can be applied to the environment of target pest(s). The resulting product retains the toxicity of the *B.t.* toxin.

30 Where the *B.t.* toxin-coding DNA is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is essential that certain host microbes be used. Microorganism hosts are selected

which are known to occupy the "phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest. These microorganisms are selected so as to be capable of successfully competing in the particular environment (crop and other insect habitats) with the wild-type
5 microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation.

A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant
10 roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera *Pseudomonas*, *Erwinia*, *Serratia*, *Klebsiella*, *Xanthomonas*, *Streptomyces*, *Rhizobium*, *Rhodopseudomonas*, *Methylophilus*, *Agrobacterium*, *Acetobacter*, *Lactobacillus*, *Arthrobacter*, *Azotobacter*, *Leuconostoc*, and *Alcaligenes*;
15 fungi, particularly yeast, e.g., genera *Saccharomyces*, *Cryptococcus*, *Kluyveromyces*, *Sporobolomyces*, *Rhodotorula*, and *Aureobasidium*. Of particular interest are such phytosphere bacterial species as *Pseudomonas syringae*, *Pseudomonas fluorescens*, *Serratia marcescens*, *Acetobacter xylinum*, *Agrobacterium tumefaciens*, *Rhodopseudomonas spheroides*, *Xanthomonas campestris*, *Rhizobium melioli*,
20 *Alcaligenes entrophus*, and *Azotobacter vinlandii*; and phytosphere yeast species such as *Rhodotorula rubra*, *R. glutinis*, *R. marina*, *R. aurantiaca*, *Cryptococcus albidus*, *C. diffluens*, *C. laurentii*, *Saccharomyces rosei*, *S. pretoriensis*, *S. cerevisiae*, *Sporobolomyces roseus*, *S. odor*, *Kluyveromyces veronae*, and *Aureobasidium pollulans*. Of particular interest are the pigmented microorganisms.

A wide variety of ways are available for introducing the *B.t.* DNA
25 expressing the toxin into the microorganism host under conditions which allow for stable maintenance and expression of the gene. These methods are well known and easily practiced by those skilled in this art. The transformants can be isolated in accordance with conventional ways, usually employing a selection technique,
30 which allows for selection of the desired organism as against unmodified organisms or transferring organisms, when present. The transformants then can be tested for pesticidal activity.

The *B.t.* cells can be treated prior to formulation to prolong the pesticidal activity when the cells are applied to the environment of a target pest. Such treatment can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the pesticide, nor diminish the cellular capability in protecting the pesticide. Examples of chemical reagents are halogenating agents, particularly halogens of atomic no. 17-80. More particularly, iodine can be used under mild conditions and for sufficient time to achieve the desired results. Other suitable techniques include treatment with aldehydes, such as formaldehyde and glutaraldehyde; anti-infectives, such as zephiran chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Bouin's fixative and Helly's fixative (See: Humason, Gretchen. L., *Animal Tissue Techniques*, W.H. Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that prolong the activity of the toxin produced in the cell when the cell is applied to the environment of the target pest(s). Examples of physical means are short wavelength radiation such as gamma-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like. The cell will usually be intact and be substantially in the proliferative form when treated, rather than in a spore form, although in some instances spores may be employed.

The treated cells generally will have enhanced structural stability which will enhance resistance to environmental conditions. Where the pesticide is in a proform, the method of inactivation should be selected so as not to inhibit processing of the proform to the mature form of the pesticide by the target pest pathogen. For example, formaldehyde will crosslink proteins and could inhibit processing of the proform of a polypeptide pesticide. The method of inactivation or killing retains at least a substantial portion of the bio-availability or bioactivity of the toxin.

The cellular host containing the *B.t.* insecticidal gene may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the *B.t.* gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting.

The *B.t.* or transformed cells may be formulated in a variety of ways. They may be employed as wettable powders, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.

Another approach that can be taken is to incorporate the spores and crystals of *B.t. Buibui* into bait granules containing an attractant and applying these granules to the soil for control of soil-inhabiting Coleoptera. Formulated *B.t. Buibui* can also be applied as a seed-coating or root treatment or total plant treatment.

The pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about 10^2 to about 10^4 cells/mg. These formulations will be administered at about 50 mg (liquid or dry) to 1 kg or more per hectare.

The formulations can be applied to the environment of the coleopteran pest(s), e.g., plants, soil or water, by spraying, dusting, sprinkling, or the like.

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 – Culturing *B.t. Buibui*

A subculture of *B.t. Buibui* can be used to inoculate the following medium, a peptone, glucose, salts medium.

5	Bacto Peptone	7.5 g/l
	Glucose	1.0 g/l
	KH ₂ PO ₄	3.4 g/l
	K ₂ HPO ₄	4.35 g/l
	Salt Solution	5.0 ml/l
10	CaCl ₂ Solution	5.0 ml/l
	Salts Solution (100 ml)	
	MgSO ₄ ·7H ₂ O	2.46 g
	MnSO ₄ ·H ₂ O	0.04 g
15	ZnSO ₄ ·7H ₂ O	0.28 g
	FeSO ₄ ·7 ¹ / ₂ H ₂ O	0.40 g
	CaCl ₂ Solution (100 ml)	
	CaCl ₂ ·2H ₂ O	3.66 g
20	pH 7.2	

The salts solution and CaCl₂ solution are filter-sterilized and added to the autoclaved and cooked broth at the time of inoculation. Flasks are incubated at 25 30°C on a rotary shaker at 200 rpm for 64 hr.

The above procedure can be readily scaled up to large fermentors by procedures well known in the art.

The *B.t.* spores and crystals, obtained in the above fermentation, can be isolated by procedures well known in the art. A frequently-used procedure is to 30 subject the harvested fermentation broth to separation techniques, e.g., centrifugation.

Example 2 - Further Methods for Culturing *B.t. Buibui*

B.t. Buibui easily grows in culture media commonly used for culturing bacteria, such as L-broth, nutrient broth, and the like, and produces spores and crystalline proteins. Inventors have reviewed highly productive media for culturing *B.t. Buibui* to produce insecticidal ingredients including the crystalline proteins.

First, 3.3×10^5 spores were inoculated into an agar medium on a 9 cm petri dish. The crystalline proteins produced in 10 days were observed through a microscope. A medium having $MnSO_4$ (10-#M) added to L-broth was the most productive, the order of productivity being as follows:

L-broth + $MnSO_4$ > spizizen + amino acid > L-broth > PGSM > spizizen + casamino acid + vitamin > spizizen + casamino acid > NYS > NYS + casamino acid.

The respective media have the following compositions:

L-broth: 10 g of tryptose, 5 g of yeast extract, and 5 g of table salt, all per 1 liter, and pH = 7.18 to 7.2.

Spizizen: 14 g of potassium 1-hydrogen phosphate (K_2H), 6 g of potassium 2-hydrogen phosphate (KH_2PO_4), 2 g of ammonium sulfate, 0.2 g of magnesium sulfate, 1 g of sodium citrate, and 5 g of glucose, all per 1 liter, and pH = 7.0.

NYS: 1.25 g of nutrient broth, 1.25 g of trypton, 0.5 g of yeast extract, 10.3 g of calcium chloride, 20.35 g of magnesium chloride, 1.0 g of manganese chloride, 0.02 g of iron sulfate, and 0.02 g of zinc sulfate, all per 1 liter, and pH = 7.2.

NYS + casamino acid: 2.0 g of casamino acid added to the above NYS medium, and pH = 7.2.

Next, in preparing an insecticide using the insecticidal crystalline proteins produced by the subject cells and effective on coleopterous larvae, the microorganisms according to the invention are cultured in the various media noted above, or in solid media such as fish meal, soy bean powder and the like, or in wastes from starch or sugar processing such as corn syrup and corn steep. The cells cultured by the various methods as above are condensed into creamy form. This is appropriately diluted with water or the like to be sprayed as an insecticide. An antiseptic, extender, and the like, may be mixed into the creamy substance by

a usual method. The creamy substance may subsequently be reduced to powder form by means of a spray dryer.

5 The above method uses the cells themselves which produce the toxin proteins. However, only the crystalline proteins may be used after culturing the cells until autolysis. The product thus obtained is used as a viable microbe cell preparation since the cells produce spores. The toxin proteins produced by these cells do not show toxicity to *Bombyx mori*. Thus, use of the viable microbe cell preparation having spores is not destructive at all to silk culture. Further, the spores may be killed with a suitable compound for use as a killed microbe cell preparation.

10 A method of spraying the above preparation will be described next. Coleopterous larva to be killed usually live in soil. Thus, the insecticide having the subject cells as an effective ingredient may be sprayed into soil, or may be scattered together with leaf mold which is immediately followed by a mixing operation with a cultivator or the like. A suspension of the above insecticide may be injected directly into soil by using an automatic or manual injector or the like. For this purpose, a fully automatic injector may be installed on a cultivator.

20 Example 3 - Insecticidal Activity of *B.t. Buibui* with Respect to *Anomala cuprea* Hope, a Coleopteran

As noted hereinabove, *Buibui* strain shows a very high degree of insecticidal activity not reported heretofore, with respect to *Anomala cuprea* Hope. The insecticidal activity of *B.t. Buibui* was examined using larvae of *Anomala cuprea* Hope in the first to third instars.

25 The activity was evaluated as follows: 2 ml of water containing insecticidal ingredients was added to 2 g of dry leaf mold. The mixture was placed in a plastic cup. The larvae were then placed one after another and kept therein for a predetermined time.

30 The insecticidal ingredients included a culture solution of *Buibui* strain (i.e., a solution containing *Buibui* strain cells) and crystalline toxin proteins isolated from the culture solution and purified. The insecticidal activity of each ingredient

was examined. It is to be noted that the death rate is the number of dead larvae divided by the total number of larvae.

Figure 8 shows how the death rate varies with lapse of time depending on quantity of the insecticidal ingredient (toxin) comprising the culture solution. It will be seen that 100% death rate is obtained with a low toxin dosage of 0.125 $\mu\text{g/ml}$ and with a high dosage of 12.5 $\mu\text{g/ml}$. It has been found, however, that twice the time is taken before all the larvae were killed in the case of a low concentration.

The term "control" in Figure 8 signifies variations occurring when only water containing no toxin is applied.

As shown in Table 5, the insecticidal ingredient comprising the crystalline proteins isolated and purified, showed insecticidal activity on its own. No insecticidal activity was detected with crystals 0.1 $\mu\text{g/ml}$. However, 100% death rate was obtained, though slowly, when the culture solution containing 130 kDa proteins in 1 $\mu\text{g/ml}$ was applied to *Anomala cuprea* Hope as noted hereinabove (Figure 8). This is considered due to the fact that spores present in the cells cooperate with the crystalline proteins in *Anomala cuprea* Hope to show the high degree of activity, and not that activity is lost due to denaturation of the proteins in the course of purification of the crystalline proteins. Thus, the insecticide may contain the cells.

Table 5. Insecticidal activities of culture solution and crystalline proteins of *Buibui* strain with respect to *Anomala cuprea* Hope

Toxin dosage (μg 130 kDa protein/ml)	Death rates* (%)		
	7th day	14th day	21st day
Culture solution			
10	60	100	
1	40	95	100
Crystalline proteins			
10	50	100	
1	0	10	20
0.1	0	0	0

*Number of samples = 20 larvae in the first instar. The cells were cultured in NYS.

Example 4 - Insecticidal Effects of *B.t. Buibui* on Larvae of Other Coleopterans

As shown in Table 6, *Buibui* strain showed a higher degree of insecticidal activity with respect also to *Anomala rufocuprea* Motschulsky, *Anomala schoenfeldti* Ohaus, apart from *Anomala cuprea* Hope. Thus, *Buibui* strain is expected to show insecticidal effect on larvae of several other *Minela splendens*. Thus, the insecticide is not limited in application to these three types of coleopterans.

Table 6. Insecticidal activities of crystalline proteins produced by *Buibui* strain with respect to *Anomala rufocuprea* Motschulsky and *Anomala schoenfeldti* Ohaus

Insects	Toxin dosage (μ g 130 kDa protein/ml)	Death rates					
		4	7	10	14	18	21st days
<i>Anomala schoenfeldti</i> Ohaus	50	0	10	20	30	60	90
<i>Anomala rufocuprea</i> Motschulsky	50	0	10	20	30	60	100
Larvae in 3rd instar of <i>Anomala rufocuprea</i> Motschulsky	50	0	10	30	30	70	90
Control	0	0	0	0	0	0	10

The insects other than the larvae in the third instar of *Anomala rufocuprea* Motschulsky were all larvae in the first instar. The crystals were purified from cells cultured in NYS. The number of samples was 10.

The term "control" above shows results obtained when only water containing no toxin is applied (in a comparative test).

Example 5 - Insecticidal Effects on Other Coleopterans

The insecticidal activity of *Buibui* strain was examined, using larvae in the first instar of *Anomala albopilosa*, larvae in the first instar of *Anomala daimiana*, larvae in the first instar of *Minela splendens*, larvae in the first instar of *Popillia japonica*, and larvae in the second instar of *Blitopertha orientalis*. The samples were young larvae hatched from eggs of adults collected outdoors and temporarily bred in a commercially available leaf mold.

The testing method was as follows: 1 gram of leaf mold dried and sterilized in a dry oven at 160°C for 60 minutes was weighed with a cup having a lid and a capacity of about 30 ml. *Buibui* culture in a predetermined concentration was mixed into the cup and sufficiently stirred, and then one larva was placed therein. A plurality of such mixtures were prepared, and bred in a thermostatic chamber at 25°C. The death rate was checked on the 7th, 14th, and 21st days to determine potency of *Buibui*. The results are shown in Table 7.

Table 7.

Larvae	Toxin dosage 130 kDa protein μg/g leaf mold	Death rates (%)		
		7th	14th	21st day
<i>Anomala albopilosa</i> in first instar	50	100	100	100
	0.1	0	0	0
<i>Anomala daimiana</i> in first instar	50	0	50	70
	0.1	25	25	25
<i>Minela splendens</i> in first instar	50	100	100	100
	0.1	0	100	100
<i>Popillia japonica</i> in first instar	50	100	100	100
	50	100	100	100
<i>Blitopertha orientalis</i> in second instar	50	100	100	100

The number of samples were 8 and 5 for *Anomala daimiana* and *Blitopertha orientalis*, respectively, and 10 for all the others.

As noted above, *Buibui* strain showed insecticidal activity with respect to *Anomala albopilosa*, *Anomala daimiana*, *Minela splendens*, *Popillia japonica*, and *Blitopertha orientalis*. In the case of *Anomala daimiana*, the death rate was 70% after 21 days, which is lower than the rates of the other insects. However, no increase in the weight was observed, and it was obvious that the larvae of *Anomala daimiana* were to die in due course. Thus, although some delays were observed, the cessation of food intake is considered equivalent to death. Particularly important is the insecticidal property to kill what are known as Japanese beetles, which are causing a serious problem in the United States.

Having determined the activity with respect to several coleopterans, the fact that the activity with respect to *Popillia*, *Minela*, and *Blitopertha* species as well as *Anomala* species suggests that the subject cells are not limited in application to those insects listed in Tables 6 and 7 but are applicable to a wide variety of coleopteran pests.

15

Example 6 - Activity of Beta-Exotoxin

Some of *Bacillus* strain cells excrete into culture media beta-exotoxin, which is a nucleotide derivative. It has an insecticidal effect similar to that of toxin proteins. Beta-exotoxin shows teratogenic action with respect to larvae of house flies, which provides a basis for evaluating the activity of beta-exotoxin. However, as shown in Table 8, when a supernatant of culture was prepared from a medium of *Buibui* strain by a usual method and applied to house flies, *Buibui* strain showed no teratogenesis with their pupation rate and eclosion rate remaining unaffected. When the above treating medium of *Buibui* strain was applied to *Anomala cuprea* Hope, its larvae remained alive after lapse of 14 days as shown in Table 9. The results of this test show that the insecticidal effect of *Buibui* strain on *Anomala cuprea* Hope does not depend on beta-exotoxin.

25

That is, beta-exotoxin does not exist to the extent of influencing the test results.

30

Table 8. Effect of beta-exotoxin in *Buibui* strain culture medium on house flies

		pupation rate (%)	eclosion rate (%)
	<i>Buibui</i> culture	86.7	80
5	Standard beta-exotoxin		
	2 ppm	90	0
	0.2 ppm	100	0
	Distilled water	93.3	93.3

10 **Table 9.** Insecticidal effect of *Buibui* strain culture medium* on *Anomala cuprea* Hope

	Death rates (%)	
	7th day	14th day
<i>Buibui</i> culture*	0	0
Distilled water	0	0

15

*The above *Buibui* medium refers to the medium remaining after strain cells are removed from the medium by centrifugal separation.

Example 7 – Insertion of Toxin Gene Into Plants

20

One aspect of the subject invention is the transformation of plants with genes coding for a coleopteran-active toxin. The transformed plants are resistant to attack by coleopterans.

25

Genes coding for coleopteran-active toxins, as disclosed herein, can be inserted into plant cells using a variety of techniques which are well known in the art. For example, a large number of cloning vectors comprising a replication system in *E. coli* and a marker that permits selection of the transformed cells are available for preparation for the insertion of foreign genes into higher plants. The vectors comprise, for example, pBR322, pUC series, M13mp series, pACYC184, etc. Accordingly, the sequence coding for the *B.t.* toxin can be inserted into the

30 vector at a suitable restriction site. The resulting plasmid is used for transformation into *E. coli*. The *E. coli* cells are cultivated in a suitable nutrient medium, then harvested and lysed. The plasmid is recovered. Sequence analysis, restriction analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each

manipulation, the DNA sequence used can be cleaved and joined to the next DNA sequence. Each plasmid sequence can be cloned in the same or other plasmids. Depending on the method of inserting desired genes into the plant, other DNA sequences may be necessary. If, for example, the Ti or Ri plasmid is used for the transformation of the plant cell, then at least the right border, but often the right and the left border of the Ti or Ri plasmid T-DNA, has to be joined as the flanking region of the genes to be inserted.

The use of T-DNA for the transformation of plant cells has been intensively researched and sufficiently described in EP 120 516; Hoekema (1985) In: *The Binary Plant Vector System*, Offset-drukkerij Kanters B.V., Alblasterdam, Chapter 5; Fraley *et al.*, *Crit. Rev. Plant Sci.* 4:1-46; and An *et al.* (1985) *EMBO J.* 4:277-287.

Once the inserted DNA has been integrated in the genome, it is relatively stable there and, as a rule, does not come out again. It normally contains a selection marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G 418, bleomycin, hygromycin, or chloramphenicol, *inter alia*. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA.

A large number of techniques are available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* as transformation agent, fusion, injection, or electroporation as well as other possible methods. If agrobacteria are used for the transformation, the DNA to be inserted has to be cloned into special plasmids, namely either into an intermediate vector or into a binary vector. The intermediate vectors can be integrated into the Ti or Ri plasmid by homologous recombination owing to sequences that are homologous to sequences in the T-DNA. The Ti or Ri plasmid also comprises the vir region necessary for the transfer of the T-DNA. Intermediate vectors cannot replicate themselves in agrobacteria. The intermediate vector can be transferred into *Agrobacterium tumefaciens* by means of a helper plasmid (conjugation). Binary vectors can replicate themselves both in *E. coli* and in agrobacteria. They

comprise a selection marker gene and a linker or polylinker which are framed by the right and left T-DNA border regions. They can be transformed directly into agrobacteria (Holsters *et al.* [1978] *Mol. Gen. Genet.* 163:181-187). The agrobacterium used as host cell is to comprise a plasmid carrying a vir region. The vir region is necessary for the transfer of the T-DNA into the plant cell. Additional T-DNA may be contained. The bacterium so transformed is used for the transformation of plant cells. Plant explants can advantageously be cultivated with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* for the transfer of the DNA into the plant cell. Whole plants can then be regenerated from the infected plant material (for example, pieces of leaf, segments of stalk, roots, but also protoplasts or suspension-cultivated cells) in a suitable medium, which may contain antibiotics or biocides for selection. The plants so obtained can then be tested for the presence of the inserted DNA. No special demands are made of the plasmids in the case of injection and electroporation. It is possible to use ordinary plasmids, such as, for example, pUC derivatives.

The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.

Example 8 – Cloning of Novel *B. thuringiensis* Genes Into Insect Viruses

A number of viruses are known to infect insects. These viruses include, for example, baculoviruses and entomopoxviruses. In one embodiment of the subject invention, ^{coleopteran} ~~ant~~-active genes, as described herein, can be placed with the genome of the insect virus, thus enhancing the pathogenicity of the virus. Methods for constructing insect viruses which comprise *B.t.* toxin genes are well known and readily practiced by those skilled in the art. These procedures are described, for example, in Merryweather *et al.* (Merryweather, A.T., U. Weyer, M.P.G. Harris, M. Hirst, T. Booth, R.D. Possee (1990) *J. Gen. Virol.* 71:1535-1544) and Martens *et al.* (Martens, J.W.M., G. Honee, D. Zuidema, J.W.M. van Lent, B. Visser, J.M. Vlak (1990) *Appl. Environmental Microbiol.* 56(9):2764-2770).

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the
5 appended claims.

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

〔 特許手続上の微生物の寄託の国際的承認に関するブダペスト条約 〕

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

下記国際寄託当局によって規則 7.1 に従い発行される

issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page.

原寄託についての受託証

氏名 (名称) 株式会社クボタ 代表取締役 三野 重和 殿
寄託者 あて名 556 大阪府大阪市浪速区敷津東1丁目2番47号

Form with sections: I. 微生物の表示 (Escherichia coli KBR9207, 受託番号 3929), II. 科学的性質及び分類学上の位置 (checked), III. 受領及び受託 (平成 4 年 7 月 13 日), IV. 国際寄託当局 (Agency for Biological Research Institute, Director General Osamu Shimizu).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Ohba, Michio
Iwahana, Hidenori
Sato, Reiichi
Suzuki, Nobukazu
Ogiwara, Katsutoshi
Sakanaka, Kazunobu
Hori, Hidetaki
Asano, Shouji
Kawasugi, Tadaaki
- (ii) TITLE OF INVENTION: Novel Microorganism and Insecticide
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: David R. Saliwanchik
(B) STREET: 2421 N.W. 41st Street, Suite A-1
(C) CITY: Gainesville
(D) STATE: FL
(E) COUNTRY: US
(F) ZIP: 32606
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Saliwanchik, David R.
(B) REGISTRATION NUMBER: 31,794
(C) REFERENCE/DOCKET NUMBER: M/K 301
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 904-375-8100
(B) TELEFAX: 904-372-5800

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3797 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis
(B) STRAIN: japonensis
(C) INDIVIDUAL ISOLATE: Buibui
- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 187..3636
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- | | |
|--|-----|
| AATTCTAATG ACACAGTAGA ATATTTTTTAA AATAAAGATG GAAGGGGGAA TATGAAAAAA | 60 |
| ATATAATCAT AAGAGTCATA CAAAAGATT GTATGTTAAA ACAA AAAAAT CCTGTAGGAA | 120 |
| TAGGGGT TTA AAAGCAATCA TTTGAAAAGA TAGTTATATT AAATTGTATG TATAGGGGGA | 180 |
| AAAAAG ATG AGT CCA AAT AAT CAA AAT GAG TAT GAA ATT ATA GAT GCT | 228 |
| Met Ser Pro Asn Asn Gln Asn Glu Tyr Glu Ile Ile Asp Ala | |
| 1 5 10 | |
| TTA TCA CCC ACT TCT GTA TCC GAT AAT TCT ATT AGA TAT CCT TTA GCA | 276 |
| Leu Ser Pro Thr Ser Val Ser Asp Asn Ser Ile Arg Tyr Pro Leu Ala | |
| 15 20 25 30 | |

TTA Leu 15	TCA Ser	CCC Pro	ACT Thr	TCT Ser	GTA Val 20	TCC Ser	GAT Asp	AAT Asn	TCT Ser	ATT Ile 25	AGA Arg	TAT Tyr	CCT Pro	TTA Leu	GCA Ala 30	276
AAC Asn	GAT Asp	CAA Gln	ACG Thr	AAC Asn 35	ACA Thr	TTA Leu	CAA Gln	AAC Asn	ATG Met 40	AAT Asn	TAT Tyr	AAA Lys	GAT Asp	TAT Tyr 45	CTG Leu	324
AAA Lys	ATG Met	ACC Thr	GAA Glu 50	TCA Ser	ACA Thr	AAT Asn	GCT Ala	GAA Glu 55	TTG Leu	TCT Ser	CGA Arg	AAT Asn	CCC Pro 60	GGG Gly	ACA Thr	372
TTT Phe	ATT Ile	AGT Ser 65	GCG Ala	CAG Gln	GAT Asp	GCG Ala	GTT Val 70	GGA Gly	ACT Thr	GGA Gly	ATT Ile	GAT Asp 75	ATT Ile	GTT Val	AGT Ser	420
ACT Thr	ATA Ile 80	ATA Ile	AGT Ser	GGT Gly	TTA Leu	GGG Gly 85	ATT Ile	CCA Pro	GTG Val	CTT Leu	GGG Gly 90	GAA Glu	GTC Val	TTC Phe	TCA Ser	468
ATT Ile 95	CTG Leu	GGT Gly	TCA Ser	TTA Leu	ATT Ile 100	GGC Gly	TTA Leu	TTG Leu	TGG Trp	CCG Pro 105	TCA Ser	AAT Asn	AAT Asn	GAA Glu	AAT Asn 110	516
GTA Val	TGG Trp	CAA Gln	ATA Ile	TTT Phe 115	ATG Met	AAT Asn	CGA Arg	GTG Val	GAA Glu 120	GAG Glu	CTA Leu	ATT Ile	GAT Asp	CAA Gln 125	AAA Lys	564
ATA Ile	TTA Leu	GAT Asp	TCT Ser 130	GTA Val	AGA Arg	TCA Ser	AGA Arg	GCC Ala 135	ATT Ile	GCA Ala	GAT Asp	TTA Leu	GCT Ala 140	AAT Asn	TCT Ser	612
AGA Arg	ATA Ile 145	GCT Ala	GTA Val	GAG Glu	TAC Tyr	TAT Tyr	CAA Gln 150	AAT Asn	GCA Ala	CTT Leu	GAA Glu	GAC Asp 155	TGG Trp	AGA Arg	AAA Lys	660
AAC Asn 160	CCA Pro	CAC His	AGT Ser	ACA Thr	CGA Arg 165	AGC Ser	GCA Ala	GCA Ala	CTT Leu	GTA Val 170	AAG Lys	GAA Glu	AGA Arg	TTT Phe	GGA Gly	708
AAT Asn 175	GCA Ala	GAA Glu	GCA Ala	ATT Ile	TTA Leu 180	CGT Arg	ACT Thr	AAC Asn	ATG Met	GGT Gly 185	TCA Ser	TTT Phe	TCT Ser	CAA Gln	ACG Thr 190	756
AAT Asn	TAT Tyr	GAG Glu	ACT Thr	CCA Pro 195	CTC Leu	TTA Leu	CCC Pro	ACA Thr	TAT Tyr 200	GCA Ala	CAG Gln	GCC Ala	GCC Ala	TCT Ser 205	CTG Leu	804
CAT His	TTG Leu	CTT Leu	GTA Val 210	ATG Met	AGG Arg	GAT Asp	GTT Val	CAA Gln 215	ATT Ile	TAC Tyr	GGG Gly	AAG Lys	GAA Glu 220	TGG Trp	GGA Gly	852
TAT Tyr	CCT Pro	CAA Gln 225	AAT Asn	GAT Asp	ATT Ile	GAC Asp	CTA Leu 230	TTT Phe	TAT Tyr	AAA Lys	GAA Glu	CAA Gln 235	GTA Val	TCT Ser	TAT Tyr	900
ACG Thr	GCT Ala 240	AGA Arg	TAT Tyr	TCC Ser	GAT Asp	CAT His 245	TGC Cys	GTC Val	CAA Gln	TGG Trp	TAC Tyr 250	AAT Asn	GCT Ala	GGT Gly	TTA Leu	948
AAT Asn 255	AAA Lys	TTA Leu	AGA Arg	GGA Gly	ACG Thr 260	GGT Gly	GCT Ala	AAG Lys	CAA Gln	TGG Trp 265	GTG Val	GAT Asp	TAT Tyr	AAT Asn	CGT Arg 270	996
TTC Phe	CGA Arg	AGA Arg	GAA Glu	ATG Met 275	AAT Asn	GTG Val	ATG Met	GTA Val	TTG Leu 280	GAT Asp	CTA Leu	GTT Val	GCA Ala	TTA Leu 285	TTT Phe	1044
CCA Pro	AAC Asn	TAC Tyr	GAT Asp 290	GCG Ala	CGT Arg	ATA Ile	TAT Tyr	CCA Pro 295	CTG Leu	GAA Glu	ACA Thr	AAT Asn	GCA Ala 300	GAA Glu	CTT Leu	1092
ACA Thr	AGA Arg	GAA Glu 305	ATT Ile	TTC Phe	ACA Thr	GAT Asp	CCT Pro 310	GTT Val	GGA Gly	AGT Ser	TAC Tyr	GTA Val 315	ACT Thr	GGA Gly	CAA Gln	1140
TCG Ser	AGT Ser 320	ACC Thr	CTT Leu	ATA Ile	TCT Ser	TGG Trp 325	TAC Tyr	GAT Asp	ATG Met	ATT Ile	CCA Pro 330	GCA Ala	GCT Ala	CTT Leu	CCT Pro	1188
TCA Ser 335	TTT Phe	TCA Ser	ACG Thr	CTC Leu	GAG Glu 340	AAC Asn	CTA Leu	CTT Leu	AGA Arg	AAA Lys 345	CCT Pro	GAT Asp	TTC Phe	TTT Phe	ACT Thr 350	1236

TTG	CTG	CAA	GAA	ATT	AGA	ATG	TAT	ACA	AGT	TTT	AGA	CAA	AAC	GGT	ACG	1284
Leu	Leu	Gln	Glu	Ile	Arg	Met	Tyr	Thr	Ser	Phe	Arg	Gln	Asn	Gly	Thr	
				355					360					365		
ATT	GAA	TAT	TAT	AAT	TAT	TGG	GGA	GGA	CAA	AGG	TTA	ACC	CTT	TCT	TAT	1332
Ile	Glu	Tyr	Tyr	Asn	Tyr	Trp	Gly	Gly	Gln	Arg	Leu	Thr	Leu	Ser	Tyr	
			370					375					380			
ATC	TAT	GGT	TCC	TCA	TTC	AAT	AAA	TAT	AGT	GGG	GTT	CTT	GCC	GGT	GCT	1380
Ile	Tyr	Gly	Ser	Ser	Phe	Asn	Lys	Tyr	Ser	Gly	Val	Leu	Ala	Gly	Ala	
		385					390					395				
GAG	GAT	ATT	ATT	CCT	GTG	GGT	CAA	AAT	GAT	ATT	TAC	AGA	GTT	GTA	TGG	1428
Glu	Asp	Ile	Ile	Pro	Val	Gly	Gln	Asn	Asp	Ile	Tyr	Arg	Val	Val	Trp	
	400					405					410					
ACT	TAT	ATA	GGA	AGG	TAC	ACG	AAT	AGT	CTG	CTA	GGA	GTA	AAT	CCA	GTT	1476
Thr	Tyr	Ile	Gly	Arg	Tyr	Thr	Asn	Ser	Leu	Leu	Gly	Val	Asn	Pro	Val	
				420						425					430	
ACT	TTT	TAC	TTC	AGT	AAT	AAT	ACA	CAA	AAA	ACT	TAT	TCG	AAG	CCA	AAA	1524
Thr	Phe	Tyr	Phe	Ser	Asn	Asn	Thr	Gln	Lys	Thr	Tyr	Ser	Lys	Pro	Lys	
				435					440					445		
CAA	TTC	GCG	GGT	GGA	ATA	AAA	ACA	ATT	GAT	TCC	GGC	GAA	GAA	TTA	ACT	1572
Gln	Phe	Ala	Gly	Gly	Ile	Lys	Thr	Ile	Asp	Ser	Gly	Glu	Glu	Leu	Thr	
			450					455					460			
TAC	GAA	AAT	TAT	CAA	TCT	TAT	AGT	CAC	AGG	GTA	AGT	TAC	ATT	ACA	TCT	1620
Tyr	Glu	Asn	Tyr	Gln	Ser	Tyr	Ser	His	Arg	Val	Ser	Tyr	Ile	Thr	Ser	
		465					470					475				
TTT	GAA	ATA	AAA	AGT	ACC	GGT	GGT	ACA	GTA	TTA	GGA	GTA	GTT	CCT	ATA	1668
Phe	Glu	Ile	Lys	Ser	Thr	Gly	Gly	Thr	Val	Leu	Gly	Val	Val	Pro	Ile	
	480					485					490					
TTT	GGT	TGG	ACG	CAT	AGT	AGT	GCC	AGT	CGC	AAT	AAC	TTT	ATT	TAC	GCA	1716
Phe	Gly	Trp	Thr	His	Ser	Ser	Ala	Ser	Arg	Asn	Asn	Phe	Ile	Tyr	Ala	
	495				500				505						510	
ACA	AAA	ATC	TCA	CAA	ATC	CCA	ATC	AAT	AAA	GCA	AGT	AGA	ACT	AGC	GGT	1764
Thr	Lys	Ile	Ser	Gln	Ile	Pro	Ile	Asn	Lys	Ala	Ser	Arg	Thr	Ser	Gly	
				515					520					525		
GGA	GCG	GTT	TGG	AAT	TTC	CAA	GAA	GGT	CTA	TAT	AAT	GGA	GGA	CCT	GTA	1812
Gly	Ala	Val	Trp	Asn	Phe	Gln	Glu	Gly	Leu	Tyr	Asn	Gly	Gly	Pro	Val	
			530					535					540			
ATG	AAA	TTA	TCT	GGG	TCT	GGT	TCC	CAA	GTA	ATA	AAC	TTA	AGG	GTC	GCA	1860
Met	Lys	Leu	Ser	Gly	Ser	Gly	Ser	Gln	Val	Ile	Asn	Leu	Arg	Val	Ala	
		545					550					555				
ACA	GAT	GCA	AAG	GGA	GCA	AGT	CAA	AGA	TAT	CGT	ATT	AGA	ATC	AGA	TAT	1908
Thr	Asp	Ala	Lys	Gly	Ala	Ser	Gln	Arg	Tyr	Arg	Ile	Arg	Ile	Arg	Tyr	
	560					565					570					
GCC	TCT	GAT	AGA	GCG	GGT	AAA	TTT	ACG	ATA	TCT	TCC	AGA	TCT	CCA	GAG	1956
Ala	Ser	Asp	Arg	Ala	Gly	Lys	Phe	Thr	Ile	Ser	Ser	Arg	Ser	Pro	Glu	
	575				580				585						590	
AAT	CCT	GCA	ACC	TAT	TCA	GCT	TCT	ATT	GCT	TAT	ACA	AAT	ACT	ATG	TCT	2004
Asn	Pro	Ala	Thr	Tyr	Ser	Ala	Ser	Ile	Ala	Tyr	Thr	Asn	Thr	Met	Ser	
				595					600					605		
ACA	AAT	GCT	TCT	CTA	ACG	TAT	AGT	ACT	TTT	GCA	TAT	GCA	GAA	TCT	GGC	2052
Thr	Asn	Ala	Ser	Leu	Thr	Tyr	Ser	Thr	Phe	Ala	Tyr	Ala	Glu	Ser	Gly	
			610					615					620			
CCT	ATA	AAC	TTA	GGG	ATT	TCG	GGA	AGT	TCA	AGG	ACT	TTT	GAT	ATA	TCT	2100
Pro	Ile	Asn	Leu	Gly	Ile	Ser	Gly	Ser	Ser	Arg	Thr	Phe	Asp	Ile	Ser	
			625				630					635				
ATT	ACA	AAA	GAA	GCA	GGT	GCT	GCT	AAC	CTT	TAT	ATT	GAT	AGA	ATT	GAA	2148
Ile	Thr	Lys	Glu	Ala	Gly	Ala	Ala	Asn	Leu	Tyr	Ile	Asp	Arg	Ile	Glu	
	640					645					650					
TTT	ATT	CCA	GTT	AAT	ACG	TTA	TTT	GAA	GCA	GAA	GAA	GAC	CTA	GAT	GTG	2196
Phe	Ile	Pro	Val	Asn	Thr	Leu	Phe	Glu	Ala	Glu	Glu	Asp	Leu	Asp	Val	
	655				660					665					670	
GCA	AAG	AAA	GCT	GTG	AAT	GGC	TTG	TTT	ACG	AAT	GAA	AAA	GAT	GCC	TTA	2244
Ala	Lys	Lys	Ala	Val	Asn	Gly	Leu	Phe	Thr	Asi	Glu	Lys	Asp	Ala	Leu	
				675					680					685		

CAG Gln	ACA Thr	AGT Ser	GTA Val 690	ACG Thr	GAT Asp	TAT Tyr	CAA Gln	GTC Val 695	AAT Asn	CAA Gln	GCG Ala	GCA Ala	AAC Asn 700	TTA Leu	ATA Ile	2292
GAA Glu	TGC Cys	CTA Leu 705	TCC Ser	GAT Asp	GAG Glu	TTA Leu 710	TAC Tyr	CCA Pro	AAT Asn	GAA Glu	AAA Lys	CGA Arg 715	ATG Met	TTA Leu	TGG Trp	2340
GAT Asp	GCA Ala 720	GTG Val	AAA Lys	GAG Glu	GCG Ala	AAA Lys 725	CGA Arg	CTT Leu	GTT Val	CAG Gln	GCA Ala 730	CGT Arg	AAC Asn	TTA Leu	CTC Leu	2388
CAA Gln 735	GAT Asp	ACA Thr	GGC Gly	TTT Phe	AAT Asn 740	AGG Arg	ATT Ile	AAT Asn	GGA Gly	GAA Glu 745	AAC Asn	GGA Gly	TGG Trp	ACG Thr	GGA Gly 750	2436
AGT Ser	ACG Thr	GGA Gly	ATC Ile	GAG Glu 755	GTT Val	GTG Val	GAA Glu	GGA Gly	GAT Asp 760	GTT Val	CTG Leu	TTT Phe	AAA Lys	GAT Asp 765	CGT Arg	2484
TCG Ser	CTT Leu	CGT Arg	TTG Leu 770	ACA Thr	AGT Ser	GCG Ala	AGA Arg	GAG Glu 775	ATT Ile	GAT Asp	ACA Thr	GAA Glu	ACA Thr 780	TAT Tyr	CCA Pro	2532
ACG Thr	TAT Tyr	CTC Leu 785	TAT Tyr	CAA Gln	CAA Gln	ATA Ile	GAT Asp 790	GAA Glu	TCG Ser	CTT Leu	TTA Leu	AAA Lys 795	CCA Pro	TAT Tyr	ACA Thr	2580
AGA Arg	TAT Tyr 800	AAA Lys	CTA Leu	AAA Lys	GGT Gly	TTT Phe 805	ATA Ile	GGA Gly	AGT Ser	AGT Ser	CAA Gln 810	GAT Asp	TTA Leu	GAG Glu	ATT Ile	2628
AAA Lys 815	TTA Leu	ATA Ile	CGT Arg	CAT His	CGG Arg 820	GCA Ala	AAT Asn	CAA Gln	ATC Ile	GTC Val 825	AAA Lys	AAT Asn	GTA Val	CCA Pro	GAT Asp 830	2676
AAT Asn	CTC Leu	TTG Leu	CCA Pro	GAT Asp 835	GTA Val	CGC Arg	CCT Pro	GTC Val	AAT Asn 840	TCT Ser	TGT Cys	GGT Gly	GGA Gly	GTC Val 845	GAT Asp	2724
CGC Arg	TGC Cys	AGT Ser	GAA Glu 850	CAA Gln	CAG Gln	TAT Tyr	GTA Val	GAC Asp 855	GCG Ala	AAT Asn	TTA Leu	GCA Ala	CTC Leu 860	GAA Glu	AAC Asn	2772
AAT Asn	GGA Gly	GAA Glu 865	AAT Asn	GGA Gly	AAT Asn	ATG Met	TCT Ser 870	TCT Ser	GAT Asp	TCC Ser	CAT His	GCA Ala 875	TTT Phe	TCT Ser	TTC Phe	2820
CAT His	ATT Ile 880	GAT Asp	ACG Thr	GGT Gly	GAA Glu	ATA Ile 885	GAT Asp	TTG Leu	AAT Asn	GAA Glu	AAT Asn 890	ACA Thr	GGA Gly	ATT Ile	TGG Trp	2868
ATC Ile 895	GTA Val	TTT Phe	AAA Lys	ATT Ile	CCG Pro 900	ACA Thr	ACA Thr	AAT Asn	GGA Gly	AAC Asn 905	GCA Ala	ACA Thr	CTA Leu	GGA Gly	AAT Asn 910	2916
CTT Leu	GAA Glu	TTT Phe	GTA Val	GAA Glu 915	GAG Glu	GGG Gly	CCA Pro	TTG Leu	TCA Ser 920	GGG Gly	GAA Glu	ACA Thr	TTA Leu	GAT Glu 925	TGG Trp	2964
GCC Ala	CAA Gln	CAA Gln	CAA Gln 930	GAA Glu	CAA Gln	CAA Gln	TGG Trp	CAA Gln 935	GAC Asp	AAA Lys	ATG Met	GCA Ala	AGA Arg 940	AAA Lys	CGT Arg	3012
GCA Ala	GCA Ala	TCA Ser 945	GAA Glu	AAA Lys	ACA Thr	TAT Tyr	TAT Tyr 950	GCA Ala	GCA Ala	AAG Lys	CAA Gln	GCC Ala 955	ATT Ile	GAT Asp	CGT Arg	3060
TTA Leu	TTC Phe 960	GCA Ala	GAT Asp	TAT Tyr	CAA Gln	GAC Asp 965	CAA Gln	AAA Lys	CTT Leu	AAT Asn	TCT Ser 970	GGT Gly	GTA Val	GAA Glu	ATG Met	3108
TCA Ser 975	GAT Asp	TTG Leu	TTG Leu	GCA Ala	GCC Ala 980	CAA Gln	AAC Asn	CTT Leu	GTA Val	CAG Gln 985	TCC Ser	ATT Ile	CCT Pro	TAC Tyr	GTA Val 990	3156
TAT Tyr	AAT Asn	GAT Asp	GCG Ala	TTA Leu 995	CCG Pro	GAA Glu	ATC Ile	CCT Pro	GGA Gly 1000	ATG Met	AAC Asn	TAT Tyr	ACG Thr	AGT Ser 1005	TTT Phe	3204
ACA Thr	GAG Glu	TTA Leu	ACA Thr 1010	AAT Asn	AGA Arg	CTC Leu	CAA Gln	CAA Gln 1015	GCA Ala	TGG Trp	AAT Asn	TTG Leu	TAT Tyr 1020	GAT Asp	CTT Leu	3252

CAA AAC GCT ATA CCA AAT GGA GAT TTT CGA AAT GGA TTA AGT AAT TGG 3300
 Gln Asn Ala Ile Pro Asn Gly Asp Phe Arg Asn Gly Leu Ser Asn Trp
 1025 1030 1035

AAT GCA ACA TCA GAT GTA AAT GTG CAA CAA CTA AGC GAT ACA TCT GTC 3348
 Asn Ala Thr Ser Asp Val Asn Val Gln Gln Leu Ser Asp Thr Ser Val
 1040 1045 1050

CTT GTC ATT CCA AAC TGG AAT TCT CAA GTG TCA CAA CAA TTT ACA GTT 3396
 Leu Val Ile Pro Asn Trp Asn Ser Gln Val Ser Gln Gln Phe Thr Val
 1055 1060 1065 1070

CAA CCG AAT TAT AGA TAT GTG TTA CGT GTC ACA GCG AGA AAA GAG GGA 3444
 Gln Pro Asn Tyr Arg Tyr Val Leu Arg Val Thr Ala Arg Lys Glu Gly
 1075 1080 1085

GTA GGA GAC GGA TAT GTG ATC ATC CGT GAT GGT GCA AAT CAG ACA GAA 3492
 Val Gly Asp Gly Tyr Val Ile Ile Arg Asp Gly Ala Asn Gln Thr Glu
 1090 1095 1100

ACA CTC ACA TTT AAT ATA TGT GAT GAT GAT ACA GGT GTT TTA TCT ACT 3540
 Thr Leu Thr Phe Asn Ile Cys Asp Asp Asp Thr Gly Val Leu Ser Thr
 1105 1110 1115

GAT CAA ACT AGC TAT ATC ACA AAA ACA GTG GAA TTC ACT CCA TCT ACA 3588
 Asp Gln Thr Ser Tyr Ile Thr Lys Thr Val Glu Phe Thr Pro Ser Thr
 1120 1125 1130

GAG CAA GTT TGG ATT GAC ATG AGT GAG ACC GAA GTG TAT TCA ACA TAGAAAGTGT 3643
 Glu Gln Val Trp Ile Asp Met Ser Glu Thr Glu Val Tyr Ser Thr
 1135 1140 1145 1149

AGAACTCGTG TTAGAAGAAG AGTAATCATA GTTCCCTCC AGATAGAAGG TTGATCTGGA 3703

GGTTTTCTTA TAGAGAGAGT ACTATGAATC AAATGTTTGA TGAATGCGTT GCGAGCGGTT 3703

TATCTCAAAAT ATCAACGGTA CAAGGTTTAT AAAT 3797

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1149 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Pro Asn Asn Gln Asn Glu Tyr Glu Ile Ile Asp Ala Leu Ser
 1 5 10 15

Pro Thr Ser Val Ser Asp Asn Ser Ile Arg Tyr Pro Leu Ala Asn Asp
 20 25 30

Gln Thr Asn Thr Leu Gln Asn Met Asn Tyr Lys Asp Tyr Leu Lys Met
 35 40 45

Thr Glu Ser Thr Asn Ala Glu Leu Ser Arg Asn Pro Gly Thr Phe Ile
 50 55 60

Ser Ala Gln Asp Ala Val Gly Thr Gly Ile Asp Ile Val Ser Thr Ile
 65 70 75 80

Ile Ser Gly Leu Gly Ile Pro Val Leu Gly Glu Val Phe Ser Ile Leu
 85 90 95

Gly Ser Leu Ile Gly Leu Leu Trp Pro Ser Asn Asn Glu Asn Val Trp
 100 105 110

Gln Ile Phe Met Asn Arg Val Glu Glu Leu Ile Asp Gln Lys Ile Leu
 115 120 125

Asp Ser Val Arg Ser Arg Ala Ile Ala Asp Leu Ala Asn Ser Arg Ile
 130 135 140

Ala Val Glu Tyr Tyr Gln Asn Ala Leu Glu Asp Trp Arg Lys Asn Pro
 145 150 155 160

His Ser Thr Arg Ser Ala Ala Leu Val Lys Glu Arg Phe Gly Asn Ala
 165 170 175

Glu Ala Ile Leu Arg Thr Asn Met Gly Ser Phe Ser Gln Thr Asn Tyr
 180 185 190
 Glu Thr Pro Leu Leu Pro Thr Tyr Ala Gln Ala Ala Ser Leu His Leu
 195 200 205
 Leu Val Met Arg Asp Val Gln Ile Tyr Gly Lys Glu Trp Gly Tyr Pro
 210 215 220
 Gln Asn Asp Ile Asp Leu Phe Tyr Lys Glu Gln Val Ser Tyr Thr Ala
 225 230 235 240
 Arg Tyr Ser Asp His Cys Val Gln Trp Tyr Asn Ala Gly Leu Asn Lys
 245 250 255
 Leu Arg Gly Thr Gly Ala Lys Gln Trp Val Asp Tyr Asn Arg Phe Arg
 260 265 270
 Arg Glu Met Asn Val Met Val Leu Asp Leu Val Ala Leu Phe Pro Asn
 275 280 285
 Tyr Asp Ala Arg Ile Tyr Pro Leu Glu Thr Asn Ala Glu Leu Thr Arg
 290 295 300
 Glu Ile Phe Thr Asp Pro Val Gly Ser Tyr Val Thr Gly Gln Ser Ser
 305 310 315 320
 Thr Leu Ile Ser Trp Tyr Asp Met Ile Pro Ala Ala Leu Pro Ser Phe
 325 330 335
 Ser Thr Leu Glu Asn Leu Leu Arg Lys Pro Asp Phe Phe Thr Leu Leu
 340 345 350
 Gln Glu Ile Arg Met Tyr Thr Ser Phe Arg Gln Asn Gly Thr Ile Glu
 355 360 365
 Tyr Tyr Asn Tyr Trp Gly Gly Gln Arg Leu Thr Leu Ser Tyr Ile Tyr
 370 375 380
 Gly Ser Ser Phe Asn Lys Tyr Ser Gly Val Leu Ala Gly Ala Glu Asp
 385 390 395 400
 Ile Ile Pro Val Gly Gln Asn Asp Ile Tyr Arg Val Val Trp Thr Tyr
 405 410 415
 Ile Gly Arg Tyr Thr Asn Ser Leu Leu Gly Val Asn Pro Val Thr Phe
 420 425 430
 Tyr Phe Ser Asn Asn Thr Gln Lys Thr Tyr Ser Lys Pro Lys Gln Phe
 435 440 445
 Ala Gly Gly Ile Lys Thr Ile Asp Ser Gly Glu Glu Leu Thr Tyr Glu
 450 455 460
 Asn Tyr Gln Ser Tyr Ser His Arg Val Ser Tyr Ile Thr Ser Phe Glu
 465 470 475 480
 Ile Lys Ser Thr Gly Gly Thr Val Leu Gly Val Val Pro Ile Phe Gly
 485 490 495
 Trp Thr His Ser Ala Ser Arg Asn Asn Phe Ile Tyr Ala Thr Lys
 500 505 510
 Ile Ser Gln Ile Pro Ile Asn Lys Ala Ser Arg Thr Ser Gly Gly Ala
 515 520 525
 Val Trp Asn Phe Gln Glu Gly Leu Tyr Asn Gly Gly Pro Val Met Lys
 530 535 540
 Leu Ser Gly Ser Gly Ser Gln Val Ile Asn Leu Arg Val Ala Thr Asp
 545 550 555 560
 Ala Lys Gly Ala Ser Gln Arg Tyr Arg Ile Arg Ile Arg Tyr Ala Ser
 565 570 575
 Asp Arg Ala Gly Lys Phe Thr Ile Ser Ser Arg Ser Pro Glu Asn Pro
 580 585 590
 Ala Thr Tyr Ser Ala Ser Ile Ala Tyr Thr Asn Thr Met Ser Thr Asn
 595 600 605
 Ala Ser Leu Thr Tyr Ser Thr Phe Ala Tyr Ala Glu Ser Gly Pro Ile
 610 615 620

Asn Leu Gly Ile Ser Gly Ser Ser Arg Thr Phe Asp Ile Ser Ile Thr
 625 630 635 640
 Lys Glu Ala Gly Ala Ala Asn Leu Tyr Ile Asp Arg Ile Glu Phe Ile
 645 650 655
 Pro Val Asn Thr Leu Phe Glu Ala Glu Glu Asp Leu Asp Val Ala Lys
 660 665 670
 Lys Ala Val Asn Gly Leu Phe Thr Asn Glu Lys Asp Ala Leu Gln Thr
 675 680 685
 Ser Val Thr Asp Tyr Gln Val Asn Gln Ala Ala Asn Leu Ile Glu Cys
 690 695 700
 Leu Ser Asp Glu Leu Tyr Pro Asn Glu Lys Arg Met Leu Trp Asp Ala
 705 710 715 720
 Val Lys Glu Ala Lys Arg Leu Val Gln Ala Arg Asn Leu Leu Gln Asp
 725 730 735
 Thr Gly Phe Asn Arg Ile Asn Gly Glu Asn Gly Trp Thr Gly Ser Thr
 740 745 750
 Gly Ile Glu Val Val Glu Gly Asp Val Leu Phe Lys Asp Arg Ser Leu
 755 760 765
 Arg Leu Thr Ser Ala Arg Glu Ile Asp Thr Glu Thr Tyr Pro Thr Tyr
 770 775 780
 Leu Tyr Gln Gln Ile Asp Glu Ser Leu Leu Lys Pro Tyr Thr Arg Tyr
 785 790 795 800
 Lys Leu Lys Gly Phe Ile Gly Ser Ser Gln Asp Leu Glu Ile Lys Leu
 805 810 815
 Ile Arg His Arg Ala Asn Gln Ile Val Lys Asn Val Pro Asp Asn Leu
 820 825 830
 Leu Pro Asp Val Arg Pro Val Asn Ser Cys Gly Gly Val Asp Arg Cys
 835 840 845
 Ser Glu Gln Gln Tyr Val Asp Ala Asn Leu Ala Leu Glu Asn Asn Gly
 850 855 860
 Glu Asn Gly Asn Met Ser Ser Asp Ser His Ala Phe Ser Phe His Ile
 865 870 875 880
 Asp Thr Gly Glu Ile Asp Leu Asn Glu Asn Thr Gly Ile Trp Ile Val
 885 890 895
 Phe Lys Ile Pro Thr Thr Asn Gly Asn Ala Thr Leu Gly Asn Leu Glu
 900 905 910
 Phe Val Glu Glu Gly Pro Leu Ser Gly Glu Thr Leu Glu Trp Ala Gln
 915 920 925
 Gln Gln Glu Gln Gln Trp Gln Asp Lys Met Ala Arg Lys Arg Ala Ala
 930 935 940
 Ser Glu Lys Thr Tyr Tyr Ala Ala Lys Gln Ala Ile Asp Arg Leu Phe
 945 950 955 960
 Ala Asp Tyr Gln Asp Gln Lys Leu Asn Ser Gly Val Glu Met Ser Asp
 965 970 975
 Leu Leu Ala Ala Gln Asn Leu Val Gln Ser Ile Pro Tyr Val Tyr Asn
 980 985 990
 Asp Ala Leu Pro Glu Ile Pro Gly Met Asn Tyr Thr Ser Phe Thr Glu
 995 1000 1005
 Leu Thr Asn Arg Leu Gln Gln Ala Trp Asn Leu Tyr Asp Leu Gln Asn
 1010 1015 1020
 Ala Ile Pro Asn Gly Asp Phe Arg Asn Gly Leu Ser Asn Trp Asn Ala
 1025 1030 1035 1040
 Thr Ser Asp Val Asn Val Gln Gln Leu Ser Asp Thr Ser Val Leu Val
 1045 1050 1055
 Ile Pro Asn Trp Asn Ser Gln Val Ser Gln Gln Phe Thr Val Gln Pro
 1060 1065 1070

Asn Tyr Arg Tyr Val Leu Arg Val Thr Ala Arg Lys Glu Gly Val Gly
1075 1080 1085
Asp Gly Tyr Val Ile Ile Arg Asp Gly Ala Asn Gln Thr Glu Thr Leu
1090 1095 1100
Thr Phe Asn Ile Cys Asp Asp Asp Thr Gly Val Leu Ser Thr Asp Gln
1105 1110 1115 1120
Thr ser Tyr Ile Thr Lys Thr Val Glu Phe Thr Pro Ser Thr Glu Gln
1125 1130 1135
Val Trp Ile Asp Met Ser Glu Thr Glu Val Tyr ser Thr
1140 1145

The claims defining the invention are as follows:-

1. A biologically pure culture of *Bacillus thuringiensis serovar japonensis* variety *Buibui* (FERM BP-3465).
2. A nucleotide sequence which codes for a toxin having activity against
5 coleopterans wherein said nucleotide sequence codes for the amino acid sequence in SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2, comprises the sequence of SEQ ID NO. 1 or a part of the sequence of SEQ ID NO. 1 that encodes a protein toxic to coleopterans, or is sufficiently homologous to the sequence of SEQ ID NO. 1 to hybridise with the sequence of SEQ ID NO. 1 under high stringency conditions.
- 10 3. The nucleotide sequence according to claim 2, wherein said sequence codes for a coleopteran-active toxin which comprises the amino acid sequence of SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2.
4. The nucleotide sequence according to claim 3, wherein said sequence comprises
15 the nucleotide sequence of SEQ ID NO. 1 or a part of the sequence of SEQ ID NO. 1 that encodes a protein toxic to coleopterans.
5. A substantially pure coleopteran-active toxin comprising the amino acid sequence of SEQ ID NO. 2 or an equivalent amino acid sequence having coleopteran activity and at least 75% homology with the amino acid sequence of SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2.
- 20 6. The toxin according to claim 5, which comprises the amino acid sequences of SEQ ID NO. 2 or a coleopteran-active part of the amino acid sequence of SEQ ID NO. 2.
7. A microorganism transformed with a nucleotide sequence of any one of claims 2 to 4.
8. A plant transformed with a nucleotide sequence of any one of claims 2 to 4.
- 25 9. Treated, substantially intact cells containing an intracellular toxin, which toxin is a gene expression product of a nucleotide sequence of any one of claims 2 to 4, wherein said cells are treated under conditions which prolong the insecticidal activity when said cells are applied to the environment of a target insect.
10. An insecticidal composition comprising as an active ingredient a toxin coded for
30 by a nucleotide sequence of any one of claims 2 to 4.
11. The insecticidal composition, according to claim 10, wherein said composition comprises a microorganism of claim 7.
12. The insecticidal composition, according to claim 10 or claim 11, wherein *Bacillus thuringiensis Buibui* is condensed into creamy form which is diluted with water for spraying in
35 liquid form.
13. The insecticidal composition, according to claim 12, wherein *Bacillus thuringiensis Buibui* is cultured in media including NYS, L-broth, bouillon medium, solid media such as fish meal and soy bean powder, and wastes from starch or sugar processing such as corn syrup and corn steep.

14. The insecticidal composition, according to claim 12 or claim 13, which further comprises an antiseptic and an extruder.

15. The insecticidal composition, according to claim 14, wherein said composition is reduced to powder form by a spray dryer.

5 16. A method for controlling coleopteran insects which comprises administering to said insects or to the environment of said insects a toxin expressed by a nucleotide sequence of any one of claims 2 to 4.

17. The method, according to claim 16, wherein a microbe which expresses said toxin is administered to said insects or their environment.

10 18. A method for controlling coleopteran insects which comprises administering to said insects or to the environment of said insects a toxin according to claim 5 or claim 6 or a composition according to any one of claims 10 to 15.

19. A biologically pure culture of *Bacillus thuringiensis serovar japonensis* variety *Buibui* (FERM BP-3465), said culture produced according to Example 1 or Example 2.

15 20. A nucleotide sequence which codes for a toxin having activity against coleopterans, said sequence substantially as hereinbefore described with reference to any one of the Examples.

21. A substantially pure coleopteran-active toxin, substantially as hereinbefore described with reference to any one of the Examples.

Dated 12 December 1996

Kubota Corporation

Mycogen Corporation

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON




Figure 1.




Figure 2

SUBSTITUTE SHEET




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/06404

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N15/32; C12N1/21;	A01N63/02; /(C12N1/21, C12R1:19)	C12P21/02; C12N15/82
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; C12R ; A01N ; C12N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	<p>JOURNAL OF INVERTEBRATE PATHOLOGY vol. 48, no. 1, July 1986, NEW YORK, US pages 129 - 130 OHBA, M. & AIZAWA, K. 'Bacillus thuringiensis subsp. japonensis (Flagellar serotype 23): a new subspecies of Bacillus thuringiensis with a novel flagellar antigen' cited in the application see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: right;">-/--</p>	1
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
09 NOVEMBER 1992	16. 11. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	ANDRES S.M.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P, X	LETTERS IN APPLIED MICROBIOLOGY vol. 14, no. 2, 29 January 1992, OXFORD, GB pages 54 - 57 OHBA, M. ET AL. 'A unique isolate of Bacillus thuringiensis serovar japonensis with a high larvicidal activity specific for scarabaeid beetles' see the whole document -----	1, 9, 17